Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts:The RituxiCAN-C4 trial by Dorling, Anthony
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.3389/fimmu.2020.00079
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Dorling, A. (2020). Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses
in Patients With Chronically Rejecting Renal Allografts: The RituxiCAN-C4 trial. Frontiers in immunology, 11,
[79]. https://doi.org/10.3389/fimmu.2020.00079
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 29. Apr. 2020
EFFECT OF OPTIMISED IMMUNOSUPPRESSION (INCLUDING 1 
RITUXIMAB) ON ANTI-DONOR ALLORESPONSES IN 2 
PATIENTS WITH CHRONICALLY REJECTING RENAL 3 
ALLOGRAFTS. 4 
Running Title: The RituxiCAN-C4 trial 5 
Authors: Kin Yee Shiu PhD1†, Dominic Stringer MSc2†, Laura McLaughlin PhD1, Olivia Shaw 6 
PhD3, Paul Brookes PhD4, Hannah Burton MRCP1, Hannah Wilkinson MRCP1, Harriet Douthwaite 7 
MRCP1, Tjir-Li Tsui MSc1, Adam Mclean DPhil5, Rachel Hilton PhD6, Sian Griffin PhD7, Colin 8 
Geddes FRCP8, Simon Ball PhD9, Richard Baker PhD10, Candice Roufosse PhD4, Catherine 9 
Horsfield FRCPath11, Anthony Dorling PhD1* 10 
†Joint first authors. 11 
 12 
Affiliations: 13 
1MRC Centre for Transplantation, Department of Inflammation Biology, King’s College London, 14 
Guy’s Hospital, London 15 
2Biostatistics and Health Informatics, The Institute of Psychiatry, Psychology & Neuroscience, 16 
King’s College London, London. 17 
3Viapath Analytics LLP, London, UK. 18 
4Histocompatibility and Immunogenetics, Imperial College Healthcare NHS Trust, London, UK. 19 
5Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, 20 
UK. 21 
6Department of Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, 22 
London, UK.  23 
7Department of Nephrology, University Hospital of Wales, Cardiff, UK. 24 
8Renal Unit, NHS Greater Glasgow and Clyde Trust, Western Infirmary, Glasgow UK. 25 
9Department of Nephrology, University Hospital Birmingham, Birmingham, UK. 26 
10Renal Unit, St Jame's University Hospital, Leeds UK.  27 
11Department of Histopathology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 28 
 29 
 30 
Word count 6100 31 
 32 
*Correspondence Professor Anthony Dorling 33 
anthony.dorling@kcl.ac.uk. 34 
  35 
 2 
Abstract:  1 
RituxiCAN-C4 combined an open-labelled randomised controlled trial (RCT) in 7 UK centres to 2 
assess whether rituximab could stabilise kidney function in patients with chronic rejection, with an 3 
exploratory analysis of how B cell-depletion influenced T cell anti-donor responses relative to 4 
outcome. Between January 2007 and March 2015, 59 recruits were enrolled after screening, 23 of 5 
whom consented to the embedded RCT. Recruitment was halted when in a pre-specified per 6 
protocol interim analysis, the RCT was discovered to be significantly underpowered. This report 7 
therefore focuses on the exploratory analysis, in which we confirmed that when B cells promoted 8 
CD4+ anti-donor IFNγ production assessed by ELISPOT, this associated with inferior clinical 9 
outcome; these patterns were inhibited by optimised immunosuppression but not rituximab. B cell 10 
suppression of IFNγ production, which associated with number of transitional B cells and correlated 11 
with slower declines in kidney function was abolished by rituximab, which depleted transitional B 12 
cells for prolonged periods. We conclude that in this patient population, optimised 13 
immunosuppression but not rituximab promotes anti-donor alloresponses associated with 14 
favourable outcomes. 15 
Registered with EudraCT (2006-002330-38) and ClinicalTrials.gov (NCT00476164) 16 
 17 
18 
 3 
Introduction 1 
Late kidney allograft failure rates remain high (1, 2), such that approximately 3% of incident kidney 2 
transplant recipients return to dialysis each year (3). Immune-mediated injury is the single biggest 3 
cause (4), usually presenting as progressive dysfunction with histological features on biopsy of 4 
chronic antibody (Ab)-mediated rejection (CAMR) (5). Despite significant advances in our ability to 5 
recognise CAMR, there are still no widely established treatments. 6 
The progressive decline in glomerular filtration rate (GFR) that precedes graft failure is highly 7 
variable (6-9), with many patients maintaining stable graft function for prolonged periods. The 8 
precise immunological factors that influence this rate of decline in GFR are unknown; differences in 9 
the IgG subclass of DSA (10) or the ability to fix complement (11) offer potential explanations. 10 
However, other factors associated with the presence of DSA might influence the progression of 11 
pathology, rate of functional deterioration and timing of eventual graft failure. There is significant 12 
debate within the field about the contribution of cell-mediated immune processes in CAMR (12). 13 
We’ve previously defined that B lymphocytes play a role in CAMR as antigen presenting cells 14 
(APC) for interferon-gamma (IFNg) production by indirect pathway anti-donor T cells, revealed in 15 
Enzyme-Linked Immunosorbent Spot (ELISPOT) assays (13). Moreover, we also defined a 16 
significant association between ELISPOT patterns of anti-donor reactivity and changes in 17 
estimated (e)GFR (14). Importantly we showed that optimising immunosuppression (IS), to 18 
influence anti-donor responses and suppress antigen presentation by B cells could stabilise graft 19 
function. These data suggested that B cell targeted therapy might have significant benefit in 20 
CAMR. 21 
Rituximab is a monoclonal Ab that binds the CD20 antigen, expressed exclusively by B cells (but 22 
not plasma cells), resulting in depletion via a range of mechanisms (15). Licensed as a treatment 23 
for B cell lymphoma, it has been used successfully in autoimmune conditions, and at induction for 24 
kidney transplantation, particularly across ABO barriers (16). Early case reports of rituximab as a 25 
treatment for CAMR suggested a benefit in stabilising eGFR (17-19), though with potentially 26 
serious infectious complications (20). 27 
Post rituximab, circulating B cell numbers can take months to recover (21, 22), with some evidence 28 
of differential recovery of different B cell subpopulations (23-26). This includes some studies that 29 
show preferential recovery of transitional B cells, a B cell subpopulation that has been associated 30 
with immunological tolerance induction in autoimmunity and transplantation (27, 28). Therefore, 31 
using rituximab to disrupt antigen presentation seemed a logical approach to treat CAMR. In 32 
RituxiCAN-C4, we tested the hypothesis that B cell depletion would stabilise graft function and 33 
reduce proteinuria in patients who had failed to respond to a formal trial of optimised oral IS. We 34 
also used the trial as an opportunity to study the impact of optimised IS and rituximab on in vitro 35 
anti-donor IFNg production, in association with its differential impact on B cell subpopulations.  36 
  37 
 4 
Materials and Methods 1 
Study design and participants 2 
In this trial, only rituximab, used within the embedded investigator-led open-label randomised 3 
controlled trial (RCT), was treated as an investigational medicinal product. At the beginning of 4 
recruitment, eligible patients were > 6 months post-transplantation, with eGFR >20 mL/min/1.73m2 5 
(by 4 variable Modification of Diet in Renal Disease equation), deteriorating kidney function (as 6 
defined by (29) and confirmed by Cockcroft-Gault eGFR) and a for-cause biopsy within 3 months 7 
of recruitment, showing chronic allograft nephropathy by BANFF ’97 criteria OR transplant 8 
glomerulopathy (TG), associated with diffuse linear C4d staining on ≥50% of peritubular (PTC) OR 9 
glomerular capillary endothelium, assessed by immunohistochemistry (IHC). Inclusion criteria were 10 
changed to improve recruitment, so that biopsy could be within 6 months of recruitment, performed 11 
for either a deteriorating eGFR or proteinuria, (urinary protein creatinine ratio (PCR) ≥50 12 
mg/mmol), and had to show either linear C4d on ≥25% of endothelium or PTCitis / glomerulitis with 13 
a combined PTC/g score of ≥2. None of these modifications were thought to alter the integrity of 14 
the trial. Biopsies were processed and interpreted locally. Each was re-interpreted according to 15 
latest BANFF criteria at study end. Exclusion criteria were 1) biopsy showing recurrent or de novo 16 
disease or calcineurin inhibitor (CNI) toxicity accompanied by supratherapeutic CNI trough levels, 17 
2) <18 years old, 3) blood group incompatible or combined kidney/pancreas transplant or 18 
desensitisation to remove HLA Ab prior to transplantation, 4) history of acute rejection, myocardial 19 
infarction, or administration of lymphocyte depleting Ab within 3 months of enrolment, 5) history of 20 
symptomatic ischaemic heart disease, or documented allergy to murine proteins and 6) history of a 21 
non-skin limited malignancy within 5 years. Post-consent screening was performed to exclude 22 
anyone with a positive HepBSAg, HepBcAb, HepCAb, HIV or HCG test (in females suspected to 23 
be pregnant) and those with ureteric obstruction on ultrasound scan. 24 
Study conduct and patient safety was monitored by an independent data monitoring committee 25 
(DMC). Clinical coordination by the chief investigator (CI) was supported by the UK NIHR Clinical 26 
Research Networks. The study was approved by the MHRA and by the West London Committee of 27 
the National Research Ethics Service (06/Q0406/119) and was carried out in accordance with the 28 
declaration of Helsinki (1996) and Good Clinical Practice as defined in UK clinical trial regulations. 29 
All subjects gave written informed consent. The trial is registered with EudraCT (2006-002330-38) 30 
and with ClinicalTrials.gov (NCT00476164). 31 
 32 
Procedures (figure 1) 33 
Patients with eligible biopsies were approached for written informed consent. After eligibility 34 
testing, IS was optimised to twice daily mycophenolic acid (MPA) formulation (dose determined 35 
locally) and tacrolimus with target trough levels of 4-8 µg/L during phase 1 (0-2 months), followed 36 
by a 3-month observational period. Patients also took statins (target cholesterol ≤ 4.5 mmol/L) and 37 
ACE-I / ARB combination therapy (target BP ≤140/≤80). Optimised therapy was individually 38 
tailored and inability to tolerate one or more aspects was not classed as ‘failure’. Patients already 39 
deemed to be on optimal therapy went straight into the 3-month observation period. 40 
At the end of phase 1, patients with an eGFR>20 mL/min/1.73m2 and either a PCR ≥50 or 41 
continued deterioration of graft function were asked to consent to the RCT. Patients not meeting 42 
criteria and those who declined consent went to phase 3, where protocol-defined interventions 43 
ceased. Study observations that contributed to the exploratory study continued to three years post-44 
recruitment. Any significant change in IS or graft failure in any phase were indications for 45 
withdrawal, including other treatments for chronic rejection such as plasmaphereis, IVIg or 46 
bortezomib. 47 
 48 
Design of the RCT  49 
Detailed descriptions of the randomisation process, blinding and interventions, primary and 50 
secondary objectives and end-points (EPs), effect size, sample size calculation for the RCT and 51 
statistical methodology are contained within the supplemental methods. Planned interim per 52 
protocol analyses (with stopping rules based primarily on adverse event frequency and secondarily 53 
on finding significant differences in response rates), were performed after recruitment of 36 (10 at 54 
primary EP) and 61 patients (20 at primary EP). Following the second interim analysis, the DMC 55 
halted further recruitment, as the trial was significantly underpowered.  56 
 57 
 5 
Statistical analysis  1 
Detailed explanation of the statistical analysis used in the RCT is contained in the supplementary 2 
material.  For the exploratory analysis, we used Fisher exact probability, Mann-Whitney (30) or 3 
Kruskal-Wallis tests as appropriate. Data are presented as median ± IQR. A value of P<0.05 was 4 
considered significant. The P values are 2 sided, and because of the nature of the study, there are 5 
no adjustments for multiple comparisons. 6 
 7 
Exploratory analysis methodology 8 
Calculation of DeGFR 9 
Measured serum creatinines at all available time points were used to calculate eGFRs by 4 10 
parameter MDRD equation, with appropriate correction for ethnicity, and these were used to 11 
generate equations describing the relationship between pre- and post-enrolment values, after 12 
normalising the enrolment eGFR to zero. The DeGFRs generated by these equations avoided 13 
misinterpretation due to significant clinic to clinic variation in observed creatinines, If a patient 14 
suffered graft failure, or was withdrawn to prepare for dialysis, the DeGFR calculated for the day of 15 
graft failure or withdrawal was used for all subsequent time points. If a patient withdrew for other 16 
reasons, no data beyond the withdrawal date was used. 17 
 18 
Anti-HLA antibody determination  19 
Peripheral blood was obtained by standard phlebotomy in plain vacutainers (BD), and allowed to 20 
clot. Samples were centrifuged, and serum stored at -80 °C until used. Analysis of anti-graft 21 
antibody was limited to donor specific antibodies (DSA) directed against HLA. Although tests for 22 
non-HLA DSA had been planned at the outset, these were not performed due to a shortage of 23 
funds. All HLA Ab testing was performed at a single laboratory (Guy’s Hospital), which is a 24 
participant in the UK National Quality Assessment Service for Histocompatibility and 25 
Immunogenetics and uses their quality controls to validate the thresholds used for positive and 26 
negative antibody testing. Screening for HLA Ab was performed by flow cytometry using xMAP 27 
(Luminex) platform, utilising LABScreen Mixed Bead. Positive samples were tested on single 28 
antigen HLA Class I and Class II kits (One Lambda, California, USA), used to further define 29 
specificity as described previously (14). No MFI cut off was applied for identification of DSA, 30 
though DSA with MFI <2000 are identified separately from those with MFI≥2000. Cumulative MFI 31 
was calculated for all DSA present, when more than one DSA was detected as previously 32 
described (31). 33 
 34 
Non-routine Laboratory analysis 35 
Preparation of responder peripheral blood mononuclear cells (PBMC) 36 
Peripheral blood samples were collected by standard phlebotomy (60ml total volume), and 37 
processed within 8 hours of venesection. PBMC were isolated by standard density gradient 38 
centrifugation using Lymphoprep (Axis-Shield, Stockport, UK). After washing, aliquots were frozen 39 
in 10% DMSO with 90% human AB serum (Life Technologies, Paisley, UK), and stored in liquid 40 
nitrogen until use. Magnetic bead separation was performed using CD8, CD19 and / or CD25 41 
Dynabeads (Life Technologies); bound cells were discarded, and the negative fraction used in the 42 
ELISPOT assay. The composition of the resulting populations is illustrated in supplementary figure 43 
1.  Importantly, CD25 depletion resulted in complete loss of all CD25++ cells, but a significant 44 
number of CD25+ cells remained. All viable samples were analysed by ELISPOT. 45 
 46 
Interferon (IFN)-gamma(g) ELISPOT Assay 47 
T cell responsiveness to alloantigens was assessed by IFNg ELISPOT analysis as previously 48 
described (13, 14).  The latter included, by necessity, flow cytometric analyses of T and B cell 49 
subsets to aid interpretation (see below). IFNγ ELISPOT plates (Mabtech AB, Nacka, Sweden) 50 
pre-coated with primary IFNγ Ab were blocked for 2 hours with ‘complete medium’ (AIM-V medium 51 
/ 10% human AB serum from Life Technologies)) before addition of 4 x 105 responder PBMC per 52 
well in 100μL of complete medium for 24 hours at 37˚C and 5% CO2, with either donor (or 53 
surrogate) proteins (at 100 and 500ng/ml), a viral antigen cocktail to control for antigen processing 54 
and presentation; anti-CD3/anti-CD28–coated beads to control for cell viability and with media 55 
alone to control for background, as previously described (13). Each condition was performed in 56 
triplicate. Standardised operating procedures were followed. All counts were normalised to 57 
 6 
background and are reported as frequency of spot-forming cells / million CD4+ cells, where CD4+ 1 
cell percentages were determined by flow cytometry.  2 
 3 
Preparation of Donor antigens 4 
PBMC were rapidly freeze-thawed three times using alternate liquid nitrogen / 37 °C water bath 5 
(32). The suspension was checked for lack of integrity of cells, ultracentrifuged at 100,000g for 60 6 
minutes at 4 °C, then resuspended in solubilising solution (6M urea, 2% CHAPS with protease 7 
inhibitor (Boehringer Mannheim, Bracknell, UK). Cells from the kidney donor were used where 8 
available, to provide the full array of HLA and non-HLA antigens.  9 
Where donor material was not available, cytoplasmic membrane protein preparations were 10 
produced from surrogate donor cells obtained from HLA-typed healthy volunteers, splenocytes 11 
collected at the time of deceased donor donation at the Hammersmith and Guy’s Hospitals in 12 
London, or from a collection of cytoplasmic membrane protein preparations obtained from tissue-13 
typed donors as previously described (33). Appropriate surrogate donors were chosen according 14 
to the following hierarchy of rules; i) shared as many as possible HLA-A, -B, -C, -DR and –DQ 15 
mismatches with the actual donor and matched as many as possible recipient HLA; ii) contained 16 
antigens that reflected the DSA profile of the recipient; iii) contained no mismatches that reflected 17 
the non-DSA profile of the recipient; iv) avoided mismatches from a previous failed transplant.  18 
 19 
Flow cytometry 20 
PBMC were thawed, washed and then stained with titrated amounts of fluorochrome-conjugated 21 
monoclonal Ab in PBS with 10% human AB serum for 30 minutes at 4 °C. Two panels were used. 22 
For T cells: CD4-FITC, CD25-PE, CD19-APC-Cy7, CD8-Qdot 605, CD14-Pacific blue, CD27-23 
PerCP-Cy5.5, CD39-PE-Cy7. For B cells CD19-APC-Cy7, CD27-PerCPCy5.5, CD24-FITC, CD38-24 
Qdot 605, CD14-Pacific blue. Ab were obtained from Ebioscience (San Diego, CA), BD Bioscience 25 
(Oxford, UK) and Life Technologies. Following staining, the cells were washed twice with PBS and 26 
then incubated with Fixable LIVE/DEAD Aqua-fluorescent reactive dye (Life Technologies) for 30 27 
minutes at 4 °C. Cells were washed, fixed for 15 minutes in 1% paraformaldehye, then washed 28 
with PBS-5% FCS and stored at 4 °C before acquisition and analysis within 24 hours on an 29 
LSRII/Fortessa flow cytometer at the BRC Flow Cytometry Laboratory, King’s College London with 30 
Flowjo software (Treestar Inc). The gating strategy was identical to that previously reported (13). In 31 
brief, B cells were defined as CD19+ single cells within the living CD14-negative lymphocyte gate. 32 
CD27 was used on CD19+ cells to identify memory from non-memory cells. CD24 and CD38 were 33 
used on the CD27- population to distinguish naïve and transitional B cells. T1 and T2 were 34 
distinguished on the the extent of CD38 and CD24 expression as defined by Cherukuri et al (28). 35 
Tregs were identified by gating on CD25+ CD4+single cells within the CD14-negative lymphocyte 36 
gate and identifying high expression of CD39. 37 
38 
 7 
Results  1 
Patients and Demographics 2 
Between January 2007 and March 2015, 62 patients were recruited from seven UK centres 3 
(supplementary table 1). Of these, 3 were deemed ineligible after screening (figure 1). The 4 
demographics of the remaining 59, including summary of biopsies are in supplementary table 2. 5 
Features of the 47 patients included in the exploratory analysis are summarised in table 1.  6 
Individual enrolment biopsies are described in supplementary table 3. Trial follow-up completed in 7 
March 2017. 8 
 9 
Results of the RCT 10 
Since the RCT element of the trial was found to be significantly underpowered, and recruitment 11 
was halted prematurely, detailed descriptions of the per-protocol RCT population, and the results 12 
of the primary and secondary endpoint analyses not described here, are contained within the 13 
supplementary text, supplementary tables 4&5 and supplementary figures 3&4. There were no 14 
significant differences in any measured primary or secondary outcomes between the 11 controls 15 
and 9 rituximab-treated patients at the planned second interim analysis and beyond.   16 
 17 
Associations and outcomes in patients after IS optimisation. 18 
The group responding poorly to optimised IS (n=32) were well matched in age, sex, ethnicity and 19 
multiple other baseline characteristics, including recruitment biopsy features, baseline 20 
immunosuppression and proportion with DSA and DSA MFI, to those who responded favourably 21 
(n=15) (table 1). However, more of poor responders had a baseline PCR >50mg/mmol and the 22 
mean PCR was significantly higher (213±211 vs. 74±74; table 1, figure 2A).  Post-optimisation, 23 
there were equal proportions established on tacrolimus, MPA, ACE-I and ARB (table 1), but the 24 
good responders had higher levels of tacrolimus (figure 2B) and better BPs (figure 2C,D). 25 
Importantly, the good responders maintained a significantly lower DeGFR over time and had lower 26 
levels of proteinuria for 12 months compared to those responding poorly to optimised IS (figure 27 
2E,F) There was a non-significant trend towards lower graft failure rates (3/15 vs. 12/32), but no 28 
differences in DSA MFI in the two groups over time (supplementary table 6, figure 2G), nor 29 
differences in adverse event rates (supplementary table 5).  30 
 31 
Changes in circulating B cells. 32 
Circulating B cells were assessed in real time from eight RCT control and seven rituximab-treated 33 
patients from 2 centres. At enrolment and end phase 1, B cell numbers were similar. Beyond 34 
phase 2, the rituximab-treated group had significantly fewer B cells to the end of year 3, with a 35 
median reduction of 98.2% (IQR 3.8%), though sample numbers at the year 3 timepoint were too 36 
small to make statistical comparisons (figure 3A).  37 
Exploratory analytical samples from nine control and eight rituximab-treated patients were 38 
analysed as described above and previously (13, 14). Immediately post-rituximab, the B cells 39 
remaining were transiently skewed towards a memory (CD27+) phenotype (figure 3B/C). Within 40 
the CD27- population, relative proportions of naive cells were similar, but transitional cell 41 
subpopulations T1 and T2 were reduced in rituximab-treated patients at all time points (figure 3D-42 
F), though statistically significant differences were only seen at end of year 1. Median absolute 43 
numbers of T1 cells were low (<1 cell per µL) at enrolment, consistent with previous reports (28). 44 
However, whilst numbers of T1 cells appeared to increase in the control population, they were 45 
undetectable post-rituximab (figure 3E). These trends were also evident when rituximab-treated 46 
patients were compared to all non-rituximab-treated controls included in the exploratory analysis 47 
(supplementary figure 2). 48 
 49 
Association between specific subsets of CD4+ and CD19+ cells and patterns of indirect pathway 50 
anti-donor IFNg production. 51 
To define associations between cell phenotype and anti-donor ELISPOT patterns, 203 samples 52 
from 51 recruits were analysed, including from 4 recruits not entered in the main exploratory 53 
analysis.  In these assays, PBMC were depleted of CD8+ (cytotoxic) T cells, before sequential 54 
depletion of CD25+ (predominantly regulatory) T cells and CD19+ (all B) cells, to assess the roles 55 
that these cell types played in the response. Figure 4 illustrates the patterns seen in these samples 56 
and how we defined them. 58/203 showed an IFNg response to donor antigens indicating the 57 
 8 
presence of specific anti-donor CD4+ T cells. In 30/58 samples, B cell depletion reduced the 1 
number of responding spots, which, as previously shown (13), suggests that B cells were 2 
presenting donor antigens. In 14 of these 30 B-dependent samples, there was an increase in the 3 
number of responding spots when CD25+ cells were depleted, indicating that regulatory T cells 4 
were suppressing these B-dependent responses.  Samples displaying this pattern of regulation 5 
contained a significantly higher proportion of CD4+CD25+CD39hi regulatory T cells, compared to 6 
other reactive samples (figure 5A). In 20/58 further samples, the number of responding spots 7 
increased when B cells were depleted, suggesting that B cells were actually suppressing anti-8 
donor CD4+ T cells. In 9 /20of these samples showing apparent regulation by B cells, this type of 9 
response was only evident when CD25+ cells were depleted; spot counts in 7/9 of these were 10 
completely suppressed when CD25+ cells were present. In the remaining 2/9 samples, the 11 
response was B-dependent when CD25+ cells were present, implying complex interactions 12 
between CD25+, CD19+ and donor reactive T cells.  Nevertheless, all 20 samples where B cells 13 
appeared to be suppressing IFNg production contained a higher proportion of T1 14 
(CD38++CD24++) or T2 (CD38+CD24+) transitional B cells (figure 5B,C). The final 8/58 samples 15 
had patterns of B-dependent responsiveness that differed depending on the dose of antigen used, 16 
making it difficult to associate patterns of responsiveness with cell phenotype,  17 
 18 
Changes in anti-donor IFNg production after optimisation of IS vs. post-rituximab. 19 
Only samples from the patients included in the exploratory analysis who had enrolment PBMC 20 
collected (n=43) were included in this analysis, and the patterns from the enrolment samples were 21 
compared to 128 samples taken from the same patients after optimisation of immunosuppression 22 
(table 2 and supplementary tables 7&8). The proportion showing either no anti-donor responses, or 23 
responses regulated by CD25+ or CD19+ cells increased, whereas those showing B-dependent 24 
responses without any evidence of regulation reduced (table 2). These data suggest that 25 
optimisation of IS inhibited unregulated B-dependent responses but promoted non-responsiveness 26 
or regulation.  27 
To examine the impact of rituximab, ELISPOT patterns from the same patients were reorganised 28 
to compare pre- and post-phase 2 patterns in patients who received rituximab to those not 29 
receiving it (including samples from outwith RCT controls) (table 3). Comparison of only those 30 
samples showing anti-donor responses revealed that post rituximab there was a reduction in the 31 
proportion of donor-reactive responses suppressed by CD25+ or CD19+ cells (such that none of 32 
the post-phase 2 donor-reactive samples from the rituximab group showed suppression by CD19+ 33 
cells and only 2 showed suppression by CD25+ cells see supplementary table 7), whilst the 34 
proportion of samples showing unregulated B-dependent IFNg production increased (table 3). 35 
These changes just failed to reach statistical significance. Together these data suggest that 36 
rituximab opposed the impact of optimised IS, by inhibiting regulated anti-donor responses, 37 
particularly by B cells, but failing to inhibit non-regulated B-dependent responses.   38 
 39 
Association between changes in anti-donor IFNg production and kidney function. 40 
27 patients had sufficient numbers of viable and interpretable ELISPOTs for analysis of dynamic 41 
change (supplementary table 7 and main table 4). Irrespective of the enrolment ELISPOT, the 42 
presence of a single non-regulated B-dependent response any time beyond end of phase 2 in 6 43 
patients was associated with a statistically significant greater fall in DeGFR at 3 years compared to 44 
21 patients who remained non-responsive or had evidence of regulated anti-donor responses 45 
(table 4). The difference in DeGFR became evident by 12 months after enrolment (figure 5D). 46 
There was no association with PCR (figure 5E). 9 of the 15 patients who responded well to 47 
optimised immunosuppression had enough ELISPOTs to be included in this analysis and none had 48 
evidence of unregulated B-dependent anti-donor responses beyond end of phase 2 49 
(supplementary table 7). In contrast, of the 18/32 patients who responded poorly to optimised IS 50 
with enough samples to be included, 6 had evidence of non-regulated B-dependent responses 51 
beyond the end of phase 2 (supplementary table 7). This included 3 of 7 who received rituximab, 1 52 
of 6 RCT controls, and 2 of 5 patients who responded poorly to optimised IS but were not 53 
randomised. These data support the conclusions made from a previous observational cohort (13, 54 
14) and suggest that the presence of non-regulated, B-cell–dependent anti-donor IFNg production 55 
 9 
after treatment with either optimised IS or rituximab is associated with a risk of significant decline in 1 
eGFR.  2 
  3 
 10 
Discussion  1 
Immune mediated injury is now recognised as an important cause of late allograft dysfunction and 2 
failure after kidney transplantation (4, 34, 35), though there are still no widely available or 3 
established treatments. The RituxiCAN-C4 trial addressed whether rituximab could stabilise graft 4 
function in patients already optimised on oral immunosuppression. This investigator led RCT was 5 
terminated prematurely when it became clear, after a planned interim analysis, that it had been 6 
significantly underpowered. Redesigning the trial, based on observed effect sizes was considered 7 
unfeasible, because the slow recruitment encountered had meant that funds to continue the trial 8 
had been used up. Nevertheless, after formal analysis of all endpoints, we found no evidence that 9 
depleting B cells after a failed trial of optimized IS could stabilise kidney function or reduce 10 
proteinuria.  11 
 12 
Since RituxiCAN-C4 started, multiple other groups have described the use of Rituximab in patients 13 
with CAMR. Seven retrospective cohort studies between 2012 and 2016 were summarised in a 14 
recent systematic review by Macklin et al (36), who noted that one reported a short-term 15 
stabilisation in eGFR and better graft survival benefit , three reported no difference and three 16 
others reported worse outcomes associated with Rituximab. A meta-analysis was not possible 17 
because of the heterogeneity of inclusion criteria and treatment protocols, most of which also 18 
included IVIg and plasma exchange. Since then, two other retrospective cohort studies in patients 19 
with CAMR have reported. Pineiro et al reported no difference in graft survival, proteinuria, eGFR 20 
and HLA antibodies between 23 patients treated with a combination of Rituximab, plasma 21 
exchange and IVIg and 39 untreated controls, but did report an increase in infections (37). Using a 22 
similar treatment protocol, Mella et al reported improvement in biopsy appearances but no 23 
differences in allograft survival, allograft function or DSA in 9 treated patients compared to 12 24 
controls (38).  Most recently, Moreso et al reported the results from Triton, the first double-blind 25 
phase IIb RCT in patients with CAMR, showing no improvement in eGFR at 12 months in 11 26 
treated vs. 12 controls, and no impact of rituximab on DSA, proteinuria or adverse events (39). 27 
RituxiCAN-C4, a similar sized RCT to Triton, has yielded entirely consistent results.  28 
 29 
In our previous observational study, we reported that optimisation of oral immunotherapy, based 30 
around achieving highest tolerated MPA dose and target trough levels of tacrolimus of 4-8 µg/ml 31 
could stabilise graft function in patients with CAMR (14), in agreement with earlier reports (40). 32 
Therefore, the first phase of RituxiCAN-C4 involved establishing all patients on these drugs, and 33 
eligibility for the RCT was assessed once the response to optimisation had been considered. This 34 
complicated the design, but also offered an opportunity to perform an exploratory observational 35 
study in all recruited patients, to study the activity of cell mediated anti-donor responses, determine 36 
whether these associated with outcome, and determine how these were influenced by different 37 
treatments. Optimised therapy was defined according to what each patient could tolerate, so 38 
patients remained enrolled even if they could not tolerate all aspects of the optimized therapy . 39 
Although Moreso et al also included a first phase during which patients were switched to 40 
tacrolimus and MPA before randomisation, they did not report the impact of this manoeuvre. We 41 
can conclude that 25% of recruits responded favourably to optimised IS. These had similar 42 
baseline kidney function and eGFR decline before enrolment as non-responders, but a greater 43 
proportion had a PCR<50 and average PCRs were significantly lower. The response to IS 44 
optimisation in this group was sustained and associated with higher trough tacrolimus levels and 45 
better BP control than seen in non-responders; unfortunately, our data does not allow further 46 
interpretation of the interplay between these factors.  47 
 48 
Rituximab had a definite measurable biological effect; it depleted >95% of circulating B cells for a 49 
prolonged period. Our data on repletion of all B cells is consistent with what has been reported in 50 
adult renal transplant recipients given a single dose of Rituximab at the time of transplantation. In 51 
this group, recovery of peripheral B cell numbers begins around 15 months (21), with <10% 52 
recovery by 24 months (22) and approximately 30% recovery by 36 months (21).   53 
However, our analysis of how B cell subpopulations repopulated after rituximab is different to 54 
what’s been reported before.  We revealed a significant and sustained reduction in the proportion 55 
of transitional cells, as detected by expression of CD24 and CD38, whilst the proportions of 56 
 11 
memory and naïve subsets quickly normalised to those seen in controls. Previous reports have 1 
suggested preferential recovery of transitional B cells, with some also describing a sustained 2 
reduction in the proportion of memory cells.  For instance, in a paediatric population, Zarkin et al 3 
used 4 doses of Rituximab (375mg/m2) with pulsed steroids to treat acute cellular rejection, 4 
showing that 12 months later (by which time peripheral B cell numbers have returned to normal in 5 
children (41)), there was a selective expansion of naive B cells, and a reduction in the proportions 6 
of memory B cells, compared to a control group treated with steroids alone (23). Sidner et al 7 
treated 9 adult dialysis patients with a single dose of Rituximab, up to 375mg/m2, and followed 8 
reconstitution for up to 2 years (24). Whilst some subsets recovered fully by 6 months, the 9 
proportion of CD27+ memory B cells remained low for up to 2 years. Kamburova et al studied 12 10 
patients receiving single dose Rituximab (375mg/m2) at the time of transplant. Within the still-11 
depleted peripheral B cell population at 24 months, there was a significant over representation of 12 
both transitional B cells (and also switched memory cells) with reduced proportions of naïve cells 13 
(22). Two other groups, using low dose Rituximab (200mg-800mg) as induction therapy or as 14 
adjunct therapy for acute rejection reported preferential expansion of transitional cells with a 15 
reduction in the proportion of memory B cells, 3-10 months post-treatment (25, 26). Therefore, the 16 
pattern of B subset repopulation we describe in this cohort is distinct from those described in these 17 
other transplant cohorts.  18 
 19 
Our exploratory analyses of IFNg production suggested a functional impact of both optimising 20 
immunosuppression and rituximab on anti-donor alloresponses. By adding whole antigens into 21 
CD8-depleted PBMC, the ELISPOT assays measure the activity of the indirect pathway of 22 
allorecognition (42), and we used changes seen when CD25+ or CD19+ cells were depleted to 23 
infer the functional impact of these cells on anti-donor responses. Where possible, we used donor 24 
antigens isolated from cells obtained either at the time of transplantation or from new samples 25 
donated by a living donor. For those where no donor material was available, we used surrogate 26 
donor cells.  Whilst these surrogates were chosen on the basis of a hierarchy of rules (listed 27 
above), designed to minimise the possibility of measuring irrelevant indirect alloresponses, it is 28 
impossible for us to be certain that we have eradicated this risk, and our data has to be interpreted 29 
with this in mind.   30 
Our results imply a level of complexity as previously described in another cohort (13), which we 31 
have tried to simplify here by describing three broad patterns: non-responsiveness, regulated anti-32 
donor IFNg production, or B dependent anti-donor responses with no evidence of regulation. These 33 
categorisations are useful as they associated with clinical outcomes in a previous cohort (14). B 34 
cell dependent responses (previously shown to indicate that B cells are presenting donor antigen 35 
to CD4+ T cells (13)), were found in 20% of samples, but in 12% of these, anti-donor reactivity was 36 
only revealed by depletion of CD25+ or CD19+ cells, indicating functional regulation of IFNg 37 
production by these cells. A further 9% showed responses in which B cells acted purely to 38 
suppress CD4+ T cell responses. Regulation of IFNg production by CD25+ T cells associated with 39 
a higher proportion of CD4+CD25+CD39hi cells, a phenotype consistent with Tregs (43), whereas 40 
regulation by CD19+ B cells associated with higher proportions of transitional B cells, a population 41 
with a known regulatory phenotype. 42 
 43 
These phenotypes appear dynamic, with some patients demonstrating all three broad patterns of 44 
ELISPOT reactivity over the course of the study. Although we have not specifically addressed why 45 
anti-donor responses detectable in PBMC change over time in some individuals, our data suggests 46 
that the changes relate to the relative proportions of CD25+ and transitional B cells present in the 47 
peripheral blood at any particular time.  We think these dynamic changes in anti-donor IFNg 48 
production have biological significance, because as we have previously reported, they associate 49 
with change in eGFR (14). Six patients had an unregulated B-dependent pattern in at least one of 50 
their samples in the follow-up period, and these had a significantly greater deterioration in eGFR, 51 
compared to others. Three of these six received rituximab. No rituximab-treated patients showed 52 
evidence of CD19+ suppressed anti-donor responses post-rituximab. Interpreted alongside the 53 
impact of rituximab on the relative proportions of transitional and memory B cell subsets, these 54 
data suggest that rituximab depleted regulatory B cells, but not those presenting donor antigen to T 55 
cells. These unique and novel observations, albeit in small numbers of patients, provide a potential 56 
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explanation for why rituximab lacks efficacy, consistent with that proposed when rituximab, used as 1 
an induction agent, appeared to cause a significant increase in acute rejection (44). 2 
 3 
We acknowledge that there are several serious shortcomings of this study. First, our biopsy 4 
inclusion criteria diverge from the widely used BANFF classification of kidney allograft pathology. 5 
From the beginning, we chose to include DSA-negative recruits and placed as much emphasis on 6 
the presence of glomerular C4d (by IHC) as PTC C4d. However, considering that DSA-neg CAMR 7 
is reported to have the same natural history and prognosis as DSA+ CAMR (45) and the diagnostic 8 
significance of glomerular C4d by IHC is now appreciated (46-48), we consider that the inclusion of 9 
these patients is justified. In addition, significant revisions of BANFF criteria have occurred since 10 
we started, most importantly removing the presence of TA/IF as evidence of damage associated 11 
with DSA (from BANFF 2013 onwards). However, the last patient in the randomised population 12 
(i.e. included in the primary endpoint analysis) was recruited on a biopsy taken in November 2013, 13 
before the formal publication of the BANFF 2013 criteria, so it would have been impossible to alter 14 
recruitment to the RCT based on BANFF 2013. Nevertheless, all biopsies have been re-examined 15 
for this report, and 17/20 patients included in the primary EP analysis had biopsies that met 16 
histological criteria for CAMR by BANFF 2013 (table 2). Of the remaining 3 not meeting these 17 
criteria, 2 lack TG or PTCBMML, but have significant TA/IF and 1 has TG but lacks both PTC C4d 18 
and microvascular inflammation scores ≥2. With regard to the exploratory analysis, 41/47 had 19 
enrolment biopsies that fulfil the BANFF 2013 histological criteria for chronic active AMR. As well 20 
as the 3 biopsies already mentioned, 1 additional biopsy lacks TG or PTCBMML but has TA/IF and 21 
2 others have evidence of TG or PTCBMML but lack PTC C4d or microvascular inflammation 22 
scores ≥2. Thus, since 85% of patients included in the RCT and 87% of those in the exploratory 23 
analysis meet present day histological criteria for chronic active AMR, we propose that our 24 
conclusions are still relevant to a modern transplant population. 25 
 26 
Second, we’ve reported that all potentially eligible patients identified from review of allograft 27 
biopsies consented to enter phase 1. However, we did not collect data on the proportion of 28 
reviewed biopsies meeting eligibility criteria, which is a potential flaw. In addition, we didn’t 29 
mandate that centres adopt uniform criteria for performing biopsies (this was a clinical decision), 30 
and the majority of patients were recruited from 2 centres, so we cannot exclude selection nor 31 
centre bias in these data.  32 
 33 
Third, our anticipated effect and sample sizes were based on a small non-randomised internal pilot 34 
(49), but this overestimated the benefits of rituximab, as revealed by the second interim analysis, 35 
so the trial was significantly underpowered. These problems were compounded by the fact that 36 
recruitment was very slow (such that funding had expired) and this impacted on the decision to halt 37 
recruitment rather than re-power the trial.  38 
 39 
Fourth, our exploratory data is also derived from small numbers of patients, particularly those from 40 
the rituximab-treated group, and as grafts failed or patients withdrew, sample numbers from the 41 
later time points in phase 3 dropped, making statistical comparisons between groups at these later 42 
time points difficult.  43 
 44 
Nevertheless, the data supports previously reported findings, providing further evidence of a link 45 
between anti-donor IFNg production and progressive loss of eGFR in patients with CAMR and 46 
suggesting that B cells appear to play a complex and dynamic role in either supporting or 47 
regulating IFNg production. Whilst optimisation of oral IS appears to suppress anti-donor IFNg 48 
production and associates with a sustained improvement in eGFR in some patients, rituximab 49 
appears to disturb the balance of the two opposing roles of B cells, by selectively reducing the 50 
relative proportion of transitional B cells (associated with regulation), while failing to sustainably 51 
deplete B cells that support anti-donor responses, for reasons that are not immediately obvious. 52 
 53 
These data suggest that newer anti-B cell therapies, to selectively target B cell subpopulations, or 54 
the distinct functions of B cells, may offer a new avenue to treat this difficult clinical problem.  55 
  56 
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Figures Legends.  1 
Figure 1 – Consort diagram for RituxiCAN-C4 trial. 2 
*Indicates 47 patients included in the exploratory analysis. 3 
† According to pre-specified second interim per protocol analysis 4 
 5 
Figure 2: Response to optimised immunosuppression 6 
Exploratory analysis comparing those who responded favourably to optimised IS with those who 7 
did not. Graphs are box and whisker plots showing median with interquartile range (IQR) with 8 
whiskers showing upper and lower limits and outliers indicated as single data points. Means are 9 
represented with ‘x’. Time points: 0= enrolment sample. EP-1; End phase 1. 0-36=months post 10 
enrolment. White bars (n=15); patients who responded well to optimised IS. Grey bars (n=31 pre-11 
enrolment. n=32 post (one recruit did not have sufficient pre-enrolment creatinines)); patients who 12 
failed to respond to optimised IS.  13 
A: Urine PCR  14 
B Tacrolimus trough levels 15 
C&D: Systolic (C) and diastolic (D) blood pressure (BP). 16 
E&F: ∆eGFR normalised to enrolment ∆eGFR of 0. 17 
G: Changes in Median Fluorescence Intensity (MFI) of cumulative DSA with time (NB includes 18 
values where DSA=0) 19 
P values by Mann Whitney U test 20 
 21 
Figure 3: Changes in B cells with rituximab – data from RCT per protocol groups 22 
Graphs are box and whisker plots showing median with interquartile range (IQR) with whiskers 23 
showing upper and lower limits and outliers indicated as single data points. Means are represented 24 
with ‘x’. White; Control group, Grey; rituximab group.. Time points: 0= enrolment sample. EP-1; 25 
End phase 1. EP-2; End phase 2. 0-36=months post enrolment. Rituximab administered between 26 
EP-1 and EP-2. The gating strategy is described in detail in methods. 27 
‘N’ refers to the number of samples at each time point. 28 
A-F: Changes in B cells in RCT 29 
A: Absolute numbers of B cells per uL of serum.   30 
B-F: Flow cytometric analysis of the proportion of B cell subpopulations against time. 31 
B: CD27-negative B cells as proportion of total CD19+ cells 32 
C: CD27+ B cells as proportion of CD19+ cells 33 
D: CD38loCD24lo cells as proportion of CD27- cells (naïve B cells). 34 
E: CD38++CD24++cells as proportion of CD27- cells (Transitional T1 cells). 35 
Median absolute number of T1 per µL is shown beneath each column. 36 
F CD38+CD324+ cells as proportion of CD27- cells (Transitional T2 cells). 37 
P values by Mann Whitney U test 38 
 39 
Figure 4: ELISPOT patterns  40 
A-E: Illustrates the 3 basic patterns of anti-donor IFNg production, displayed as the spot count 41 
(corrected for flow cytometric assessment of CD4+ cell proportions) present under 4 different 42 
conditions: CD8- (CD8-depleted PBMC); CD19- (CD8- & CD19-depleted PBMC), both performed 43 
in presence or absence of CD25+ cells. Samples showing anti-donor responsiveness from 51 44 
recruits, including from those not in the exploratory analysis, are represented. 45 
A: Pattern 1: Unregulated B cell-dependent pattern. Showing spot counts that reduce (>20%) on 46 
depletion of CD19+ cells in presence of CD25+ cells (± in absence of CD25+ cells). N=16 47 
samples. 48 
B&C: Pattern 2: B cell-dependent anti-donor patterns with evidence of regulation.1  49 
B: CD25+ regulated B-dependent responses: B cell-dependent anti-donor responses only 50 
detectable in absence of CD25+ cells. N=14 samples. 51 
 
1 NB. 8 samples showed CD25+ or CD19+ regulated B-dependent patterns that were dependent on dose of 
antigen and these are not represented here. 
 15 
C: CD19+ regulated B-dependent responses. B cell-dependent anti-donor responses in presence 1 
of CD25+ cells, but when CD25+ cells absent, depletion of CD19+ cells increases spot count 2 
(>20%), indicating evidence of regulation by B cells. N=2 samples. 3 
D&E: Pattern 3: Regulated anti-donor responses without evidence of B cell-dependency. 4 
D: CD19+ regulated responses; In presence of CD25+ cells, spot counts increase (>20%) when 5 
CD19+ cells are depleted. N=11 samples. 6 
E: CD25+ and CD19+ regulated. In absence of CD25+ cells, depletion of CD19+ cells increases 7 
spot counts (>20%). In presence of CD25+ cells, anti-donor responses are undetectable. N=7 8 
samples. 9 
 10 
Figure 5: Associations with ELISPOT patterns. 11 
Graphs show box plots of median with IQR with whiskers showing upper and lower limits and 12 
outliers indicated as single data points. Means are represented with ‘x’.  13 
A: Association between proportion of CD4+CD25+CD39hi T cells (Tregs) and ELISPOT patterns 14 
characterised by spot count suppression when CD25+ cells present 15 
B&C: Association between proportion of CD19+ cells having the phenotype of transitional T1 cells 16 
(CD27-CD38++CD24++) (B) or transitional T2 cells (CD27-CD38+CD24+) (C) and ELISPOT 17 
patterns showing evidence of increasing spot counts after depletion of CD19+ cells. 18 
D&E: ∆eGFR, normalised to enrolment eGFR of 0 (D) and urine PCR (E) in patients with at least 19 
two samples at end-phase 2 or beyond (n=27). White bars are patients who had either donor non-20 
responsiveness or ELISPOT patterns with evidence of regulated anti-donor responses in their 21 
post-optimisation samples (n=21). Grey bars are those with at least one post-end-phase 2 sample 22 
showing evidence of unregulated B cell dependent anti-donor responses (n=6). Time points: 0= 23 
enrolment sample. EP-1; End phase 1. EP-2; End phase 2. 0-36=months post enrolment. P values 24 
by Mann Whitney U test.  25 
 26 
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Table 1 – Baseline characteristics of the patients included in the exploratory analysis. 1 
 2 
  Poor response to IS (N=32)2 Good response to IS (N=15) P3    
Age (Years - Median (IQR))  44 (22.7) 46 (13) ø  
Male n (%)  23 (72) 9 (60) ø  
Ethnicity n (%) 
Asian: Black: White 
  
4(12.5): 3(9.4): 25(78.1) 
 
2(13.3): 2(13.3): 11(74.3) 
 
ø 
 
Cause of renal failure n 
DM 
APKD 
GN 
SLE 
HT 
Congenital4 
TIN5 
Cystinosis 
HUS 
CNI toxicity 
Unknown / not recorded 
  
- 
2 
10 
1 
2 
8 
5 
2 
- 
- 
2 
 
- 
- 
7 
1 
1 
1 
1 
- 
1 
16 
2 
 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
 
Transplant history; 
Deceased: LRD: LURD 
Previous transplants: 0: 1 
Time from Tx (years-median (IQR)) 
HLA MM (Mean (SD)) 
Overall 
A: B:  
DR 
  
22: 8: 2 
26: 6 
12.8 (14.4) 
 
2.9 (1.4) 
1.1(0.6): 1.1(0.7) 
0.7 (0.5) 
 
6: 6: 3 
14: 1 
16.6 (12.7) 
 
3.3 (1) 
1(0.8): 1.3(0.7) 
1.2 (0.5) 
 
ø 
ø 
ø 
 
ø 
ø 
* 
 
HLA Ab status 
CRF (Mean (SD)) 
DSA+ n (%) 
-Class I: Class II: Both 
-NA 
DSA MFI7 (Mean (SD)) 
  
48.1 (13.9)8 
17 (53) 
10(31): 3(9.7): 4(12.9) 
15 (47) 
4437 (6627) 
 
42.7 (37.7) 
11 (74.3) 
3(20): 5(33.3): 3(20) 
4 (26.7) 
6758 (8998) 
 
ø 
ø 
ø 
ø 
ø 
 
Enrolment biopsy scores – median 
(IQR) 
C4d glom9 
Banff C4d (PTC) 
Bannf g 
Banff ptc 
Banff cg 
Banff cv 
Banff ct 
Banff ci 
TA/IF (%) 
  
 
3 (1) 
2 (2) 
2 (1) 
1 (2) 
2 (2) 
1 (1) 
1 (1) 
1 (1) 
25 (14) 
 
 
3 (1) 
2 (2) 
1(2) 
1 (1) 
1 (1) 
1.5 (1) 
1 (1) 
1 (1) 
20 (20) 
 
 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
ø 
 
Baseline immunosuppression n (%) 
Tac: CsA 
MPA; Azathioprine 
  
19 (59): 6 (19) 
22 (69): 5 (16) 
 
8 (53): 7 (47) 
9 (60): 5 (33) 
 
ø 
ø 
 
Baseline renal function (Mean (SD)) 
Creatinine10 
eGFR11 
  
184.8 (51.7) 
37.7 (11.6) 
 
168.7 (44.8) 
38.6 (11.3) 
 
ø 
ø 
 
 
2 All who were eligible for RCT + the patient (G008) who developed a contraindication to Rituximab during phase 1 
3 P value, comparing good response to optimised IS (N=15) to all poor response to optimised IS, eGFR>20 (N=32) 
4 Including Alports 
5 Including chronic pyelonephritis 
6 Heart transplant recipient 
7 Cumulative - includes those with DSA=0 
8 No HLA Ab data available on 1 recruit 
9 Scored as C4d PTC 
10 µmol/L 
11 mls/min/1.73 m2  
 20 
1/creat slope 
Formally deteriorating 
PCR12  (Mean (SD)) 
PCR >50 
-0.15 (0.23) 
23 (72) 
213 (211) 
27 (84) 
-0.07 (0.07) 
10 (67) 
74 (74) 
8 (53) 
ø 
ø 
† 
* 
Post-optimisation medication 
Tac n (%) 
Tac level (Mean (SD)) 
MPA n (%) 
MPA dose (mg (SD)) 
On ACE-I n (%) 
On ARB n (%) 
  
31 (97) 
5.4 (2.7) 
30 (94) 
953 (493) 
20 (62.5) 
22 (68.8) 
 
15 (100) 
7.0 (2.2) 
15 (100) 
1000 (422) 
6 (40) 
12 (80) 
 
ø 
* 
ø 
ø 
ø 
ø 
 
 1 
øP=NS 2 
†P≤0.005 3 
*P<0.05 4 
1o renal diagnosis: DM=diabetes mellitus: APKD=adult polycystic kidney disease: 5 
GN=glomerulonephritis: SLE=systemic lupus erythematosus: HT=hypertension: 6 
TIN=tubulointerstitial nephritis: HUS=haemolytic uraemic syndrome: CNI=calcineurin inhibitor. Tx 7 
type: LURD: living unrelated donor. LRD: living-related donor. HLA MM; Number of Class I (A,B) 8 
and Class II (DR) mismatches. Two patients (B003 and W007) had their transplants abroad and 9 
tissue typing was unavailable. HLA Ab status: CRF=calculated reaction frequency. DSA=donor 10 
specific antibody. MFI=cumulative median fluorescence intensity. Means are shown for whole 11 
group, including those with MFI of 0.  Enrolment biopsy scores: g=glomerular inflammation. 12 
ptc=peritubular capillary inflammation. c= chronic scores. TA/IF=tubular atrophy/interstital fibrosis. 13 
Immunosuppression; Tac = Tacrolimus; CsA= ciclosporin; MPA= Mycophenolic acid or 14 
mycophenolate mofetil. Baseline renal function: eGFR= estimated glomerular filtration rate (4 value 15 
MDRD). Formally deteriorating =meet criteria for deteriorating function based on analysis of 16 
1/creatinine plot. Medication: ACE-I= angiotensin converting enzyme inhibitor: ARB= angiotensin II 17 
receptor blocker.  18 
 
12 mg/mmol 
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Table 2 - IFNg production patterns in ELISPOTs of 171 samples from 43 patients in the exploratory 1 
analysis, comparing patterns at enrolment, with those following optimisation. 2 
 3 
Interpretation based on pattern of anti-
donor responsiveness 
Number of samples (%)  
Enrolment 
(n=43)* 
Post-optimisation 
(n=128) 
Total 
(n=171) 
No response 26 (60.5%) 89 (69.5%) 115 (67.3%) 
CD25+ or CD19+ regulated  8 (18.6%)  29 (22.6%) 37 (21.6%) 
B-dependent - no regulation 8 (18.6%) 8 (6.3%) 16 (9.3%) 
Not viable / Not interpretable 1 (2.39%) 2 (1.6%) 3 (1.8%) 
*This analysis is of samples from 43 of the 47 recruits included in the exploratory analysis, who 4 
had enrolment PBMC collected. 5 
Comparing enrolment vs post-optimisation patterns in a Fisher 2x3 exact probability test ((No 6 
response + regulated response) vs. B-dependent responses vs. non-viable), p=0.04. 7 
 8 
Refer to supplementary tables 7&8 to see the individual ELISPOTs from all 43 patients included in 9 
this table 10 
 11 
 12 
  13 
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Table3: Anti-donor IFNg production patterns in ELISPOT arranged to illustrate the effect of 1 
rituximab 2 
 
Exploratory group 
 
No Rituximab Rituximab 
Be
fo
re
 e
nd
 p
ha
se
 2
 CD25+ or CD19+ regulated anti-donor 
response  9 8 
B-dependent anti-donor response – no 
regulation 7 3 
En
d 
ph
as
e 
2 
an
d 
be
yo
nd
* 
CD25+ or CD19+ regulated anti-donor 
response 18 2 
B-dependent anti-donor response – no 
regulation 3 3 
Samples from the same population as that represented in table 2, re-organised according to 3 
whether patients received rituximab or not. 4 
Differences between groups compared by Fisher 2x2 Exact probability test  5 
Comparing Elispot patterns in pre-phase 2 samples from those not receiving rituximab with those 6 
receiving rituximab; p=0.44. In contrast, comparing patterns in post phase 2 samples from those 7 
not receiving rituximab with those receiving rituximab; p=0.06.   8 
*i.e. post-rituximab in rituximab-treated patients 9 
 10 
Refer to supplementary tables 7&8 to see the individual ELISPOTs from all 43 patients included in 11 
this table 12 
  13 
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Table 4: Dynamic changes in ELISPOT patterns in twenty seven patients with viable and 1 
interpretable enrolment samples and at least two viable and interpretable samples at or beyond 2 
end of phase 2. 3 
 4 
  ELISPOT patterns at or beyond end phase 2 
  No response OR CD25+/CD19+ regulated anti-donor response 
B-dependent anti-donor response 
– no evidence of regulation* 
Pr
e-
en
d 
ph
as
e 
2  
 Any 
ELISPOT 
pattern 
 
N=21 (4)†  
 
Median DeGFR -9.41  
(IQR 9.5) ø 
 
 
N=6 (3) 
 
Median DeGFR -20.55  
(IQR 7.8)ø 
 
 5 
* Only includes patients with enrolment and 2 or more viable and interpretable post treatment 6 
ELISPOTs. If any of these ELISPOTs showed evidence of non-regulated B-dependent anti-donor 7 
IFNg production, the patient is included in one of these two columns.  8 
† Numbers in parentheses indicate the number with failed grafts or withdrawals due to IS reduction 9 
as a prelude to starting dialysis. 10 
ø Comparison of median DeGFR at 3 years: p=0.02 by Mann Whittney U 11 
 12 
Refer to supplementary table 7 to see the individual ELISPOTs from all 27 patients included in this 13 
table 14 
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Supplementary Methods: 
 
Procedures (refer to main figure 1) 
Optimised therapy was individually tailored and inability to tolerate one or more aspects was not 
classed as ‘failure’. Patients already deemed to be on optimal therapy went straight into a three-
month observation period. 
At the end of phase 1, patients with an eGFR>20 >20 mL/min/1.73m2, a PCR ≥50 or continued 
deterioration of graft function on analysis of a reciprocal creatinine plot , were eligible for the RCT. 
These patients were asked to consent specifically to randomisation. Patients not meeting criteria 
and those who refused consent went straight to phase 3, where all protocol-defined interventions 
ceased, but study observations continued every 3 months for three years post-recruitment.  A 
significant change in IS in any phase was considered a reason for withdrawal. All patients requiring 
dialysis or re-transplantation were also withdrawn.  
 
Randomisation  
Allocation to treatment or control arms was assigned (1:1) by permuted variable block 
randomisation with random block sizes of 4 or 6. Randomisation was carried out using sequentially 
numbered opaque envelopes sealed by an independent party in the Pathology Department of 
Hammersmith Hospital. Block sizes and the allocation schedule were concealed from trial 
investigators. Following the first interim analysis in July 2011, randomisation was stratified by graft 
function and proteinuria to ensure equal allocation to each arm, with generation of a new series of 
envelopes. Envelopes were opened by the CI once consent to the RCT was obtained by the local 
investigator. 
 
Interventions and blinding 
All remained on optimised IS. Controls received no additional treatment. Rituximab treatment 
consisted of two 1g infusions 14 days apart, administered with paracetamol and chlorpheniramine 
+/- hydrocortisone, followed by co-trimoxazole (or alternative) for 6 months. Blinding was 
considered unworkable as circulating B cells were measured as a secondary endpoint (EP).  
 
Primary objective and EP 
The primary objective was to determine whether rituximab could stabilise kidney function and/or 
reduce proteinuria after optimised IS had failed. The primary EP was 3-5 months post-
randomisation (dependent on trial arm). There were two co-primary outcome measures:  
• Rate of deterioration in graft function, defined by individual slope of the reciprocal creatinine plot 
(over the preceding 3 months). Slope was assessed continuously, but also as a binary measure, 
with ‘deterioration’ defined as a negative individual slope with an adjusted R2>0.35 and p<0.05 (1). 
• Change in PCR (as continuous measure).  
 
Secondary outcomes 
Secondary outcomes, determined 3-5 months post-randomisation and at 1, 2- and 3-years post-
recruitment, were: a) deterioration in function (slope of reciprocal creatinine plot since the previous 
assessment): b) patient and c) graft survival: Incidence of d) infection (with diagnostic certainty) 
and e) malignancy: Changes in f) PCR, g) anti-graft Ab, h) circulating CD20+ cells and i) T cell 
responsiveness to donor alloantigens. 
 
Effect size and sample size calculation 
A pilot study was performed on 10 consecutive patients between November 2005 and October 
2006, all of whom had for-cause biopsies for allograft dysfunction showing CAN by Banff ’97 
criteria and chronic transplant glomerulopathy associated with diffuse linear C4d staining on > 50% 
of PTC or glomerular capillary EC (using polyclonal antibody to C4d) (2). Five patients required 
optimisation of oral therapy and were converted from their baseline drugs onto tacrolimus and 
MMF. Of these, 3/4 (75%) stabilized within 3 months of optimisation and a fourth stabilized 3-6 
months after optimisation. The fifth patient failed to stabilize so received 2 doses of rituximab. The 
other 5 patients were already on optimal doses of tacrolimus and MMF and therefore received two 
doses of rituximab. Of the six who received rituximab, four (2/3rd) showed a short-term stabilisation 
of eGFR. The two remaining patients continued to deteriorate at the same rate as before rituximab. 
  S2 
Based on this experience, we made 3 assumptions: a) that 75% of recruits would stabilise within 3 
months after optimisation on tacrolimus and MMF; b) that a minority (1/5) who failed to stabilise 
within 3 months would stabilise within 6 months – this informed the proportion of RCT control arm 
recruits who would stabilise (i.e. 20%); c) that a majority (4/6) who received Rituximab would show 
short term stabilisation of eGFR (we rounded up to 70%).Based on these responses, we aimed to 
recruit 120, to ensure that 30 randomised patients reached the primary EP, which would allow 
detection of 70% response rate in rituximab-treated vs. 20% response rate in controls, with alpha 
of 0.05 and beta 0.83.  Planned interim per protocol analyses (with stopping rules based primarily 
on adverse event frequency and secondarily on finding significant differences in response rates), 
were performed after recruitment of 36 (10 at primary EP) and 61 patients (20 at primary EP). 
Following the second interim analysis, the DMC halted further recruitment, as the trial was 
significantly underpowered.  
 
Statistical analysis  
Analyses of the primary objective used the per-protocol population as specified in the protocol 
(provided as a supplement), as recruits who withdrew prior to the primary EP were replaced in the 
RCT by another eligible participant. Intention to treat analyses were performed as sensitivity 
analyses where data was available. For continuous outcomes, longitudinal linear mixed models 
were used. 4 arms of the study (both randomised arms plus 2 observational groups; ‘eligible for 
RCT but not randomised’ and ‘not eligible for RCT as responded favourably to IS optimisation’) 
were modelled together for efficiency. Recruits not eligible for the RCT on the basis of eGFR<20 
were not included in any analyses.  
Post-estimation methods were used to extract randomised comparisons between the two arms of 
the RCT (and for the longitudinal analyses to extract comparisons between the 2 observational 
groups). These models used all available measures beyond end of phase 1 with a random 
intercept to account for dependency of repeated measurements, adjusting for end of phase 1 and 
enrolment values. The randomisation stratifier (binary measure of having deteriorating graft 
function +/- proteinuria vs. proteinuria only) was also adjusted for. Due to the variation in time 
measurements collected for each timepoint, time was treated continuously, with observed time of 
measurements used (months since end of phase 1) rather than the specified discrete timepoints. 
Post-estimation was used to then estimate differences at these discrete timepoints. These were 
defined as 4,8,20 and 32 months beyond end of phase 1, to match up with 3-5 months post-
randomisation, and 1,2- and 3-years post-enrolment respectively.  A treatment x time interaction 
was included in the model. A quadratic term for time was included in the model to account for non-
linearity over time. Models used restricted maximum likelihood (REML) estimation with missing 
outcomes assumed to be missing at random. A similar approach using generalisations of the 
longitudinal linear mixed model were planned for non-continuous outcomes where data allowed. 
Where data was not sufficient, simpler non-parametric models were used, or the data has been 
described only. No correction was applied to account for multiple testing, either for the co-primary 
outcomes or for the numerous secondary outcomes or to account for the interim analyses as no 
corrections were pre-specified. However, all analyses were interpreted conservatively. 
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Supplementary Results 
Per protocol population for the RCT 
Control and rituximab groups were randomly matched for enrolment criteria except time from 
transplantation to enrolment and mean fluorescence intensity (MFI) of donor specific Ab (DSA) 
(supplementary table 2). All 11 controls reached primary EP so were included in the per-protocol 
analysis. 3 from the rituximab group were excluded from the per-protocol population (main figure 
1). Of the 8 per protocol rituximab recruits who completed phase 2, 7 were administered both 
doses of rituximab. The second dose was withheld in the eighth after hospitalisation for an 
unrelated event. The ninth patient, who received both doses, died during phase 2 (see below) but 
had sufficient data to include in the primary analysis. 
 
Results of the RCT: Primary analysis (second interim timepoint) (supplementary table 4). 
Using the co-primary outcomes, there was a small but statistically insignificant estimated mean 
difference in favour of rituximab in 1/creatinine slopes at 3-5 months post-randomisation from the 
longitudinal model (0.14 [CI: -0.02, 0.31]; p=0.087). There was no difference in PCR (4.0 [CI: -
135.93, 131.49] p=0.95) or odds ratio of formal deterioration of function (0.31 [CI: 0.01-7.13] 
p=0.46) based on regression analysis of the 1/creatinine plot. 
 
Results of the RCT: Secondary EP analysis. 
a) Deterioration in renal function (supplementary table 4). 
There were no significant differences in the 1/creatinine slopes for rituximab vs. controls from the 
longitudinal model, nor in the proportion judged to be deteriorating by formal regression analysis. 
Four controls and three rituximab-treated patients, all of whom had deteriorating graft function at 
enrolment, appeared to develop stable or improving graft function. Individual 1/creatinine plots for 
the per protocol groups, as well as an illustration of changes in DeGFR (exploratory) are shown in 
supplementary figure 3. 
 
b) Change in proteinuria (supplementary table 4). 
There were no significant differences in proteinuria when the urine PCR was assessed 
continuously between groups at any time point. All had a PCR ≥50 at the end of phase 2.  
 
c) Patient survival: 
One patient died 15 weeks after the second dose of rituximab and 3 days following emergency 
replacement of a ruptured aortic valve. Although the event was reported as possibly due to 
rituximab, at post-mortem only old infective endocarditis was found, with no evidence of new 
infection. 
 
d) Graft Survival 
3/11 control grafts failed, and 2 others withdrew following significant IS reduction in preparation for 
HD. In the rituximab group, 3/11 grafts failed and another withdrew following IS reduction 
immediately prior to beginning HD. There was no difference in time to graft failure between the 
rituximab and control groups using Cox regression [Hazard ratio 1.58, 95% CI 0.33, 7.37]. Log 
rank tests at each follow up time point also showed no difference by group. 
 
e) Incidence of infections with diagnostic certainty (supplementary table 5).  
10 infections (in 5 patients) were documented after rituximab vs. 7 in controls (in 6 patients) 
(p=NS). As well as endocarditis (see above), one pneumonia with CMV viraemia and one skin 
abscess were reported as potentially related to rituximab. 
 
f) Incidence of malignancy (supplementary table 5). 
There were 2 new neoplasms in the rituximab group vs. 3 in controls (p=NS). In the rituximab 
group, a stomach adenocarcinoma presented after withdrawal and was reported as potentially 
related to rituximab. 
 
g) Other adverse events: 
See supplementary table 5. Of note, in the RCT population there were 6 adverse drug reactions 
related to IS optimisation. 
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h) Changes in circulating DSA (supplementary table 6). 
In the RCT population, there were no significant differences in the proportion in either arm with 
DSA, nor in DSA MFI beyond enrolment. 3 recruits had inadequate tissue typing to identify 
potential DSA against donor HLA-DQ. 1 in each group developed de novo DSA during phase 3. 
Three with DSA at enrolment became DSA-negative after optimisation but re-gained DSA in phase 
3, 2 of whom received rituximab. There was no association between DSA and graft failure. 
Individual plots of MFI of DSA for the per protocol groups, as well as an illustration of changes in 
median MFI for each group (exploratory) are shown in supplementary figure 4. 
 
i)Changes in circulating CD20+ cells (main figure 3). 
These are described in the main manuscript 
 
f) Changes in T cell responsiveness to alloantigens by IFNg ELISPOT. 
80 samples from 19 patients were analysed by anti-donor IFNg ELISPOT. Because of the 
complexity of the patterns of ELISPOT responsiveness, those from the RCT recruits, and changes 
related to rituximab, are described as part of the exploratory analysis in the main manuscript. 
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Supplementary Figure Legends 
Figure 1: Depletion of subsets in ELISPOT PBMC 
To illustrate the sequential deplation of CD8, CD19 and CD25 cells from PBMC before use in 
ELISPOT assay. Panels show whole PBMC (A), followed by CD8-depleted PBMC (B: used as the 
‘baseline’ population in ELISPOT, followed by the impact of c0-depleting CD19 (C) , CD25 (D) and 
both CD19 and CD25 (E). Importantly, when CD25 cells are depleted, CD25++ cells are 
completely depleted but a significant number of CD25+ cells remain (bottom two rows). 
 
Figure 2: Changes in B cells with rituximab – data from whole exploratory group 
Graphs are box and whisker plots showing median with interquartile range (IQR) with whiskers 
showing upper and lower limits and outliers indicated as single data points. Means are represented 
with ‘x’. White; Control group exploratory study, Grey; per protocol rituximab group. P values by 
Mann Whitney U test. Time points: 0= enrolment sample. EP-1; End phase 1. 0-36=months post 
enrolment. Rituximab administered between EP-1 and 12 months. ‘N’ refers to the number of 
samples at each time point. 
A-F: Changes in B cells  
A: Absolute numbers of B cells per uL of serum.   
B-F: Flow cytometric analysis of the proportion of B cell subpopulations against time. 
B: CD27-negative B cells as proportion of total CD19+ cells 
C: CD27+ B cells as proportion of CD19+ cells 
D: CD38loCD24lo cells as proportion of CD27- cells (naïve B cells). 
E: CD38++CD24++cells as proportion of CD27- cells (Transitional T1 cells). 
Median absolute number of T1 per µL is shown beneath each column. 
F CD38+CD324+ cells as proportion of CD27- cells (Transitional T2 cells). 
 
 
Figure 3: Evolution of graft dysfunction for the per protocol control and Rituximab-treated 
populations. 
A&B: Graphs show 1/creatinine plots against time (days) for the people included in the primary 
endpoint analysis of the RCT in control (A) or Rituximab-treated (B) groups. All creatinine data 
included. Time 0 is the day of enrolment. Dots are colour coded to indicate the phase of the study. 
Green =pre-enrolment. Yellow = phase 1. Red = Phase 2. Blue = phase 3.  Graphs annotated with 
time of Rituximab administration and day of withdrawal or graft failure. A negative slope on this 
graphical representation indicates deteriorating graft function. 
C: From the exploratory analysis. Box and whisker plot showing median ∆eGFR (normalised to 
enrolment eGFR of 0), with interquartile range (IQR) with whiskers showing upper and lower limits 
and outliers indicated as single data points. Means are represented with ‘x’. White; control group, 
Grey; Rituximab group. P values by Mann Whitney U test 
Time points: 0= enrolment sample. EP-1; End phase 1. EP-2; End phase 2. 0-36=months post 
enrolment 
 
Figure 4: Changes in DSA in the per protocol control and Rituximab-treated populations. 
A: Box and whisker plots showing median cumulative MFI of all DSA with interquartile range (IQR) 
with whiskers showing upper and lower limits and outliers indicated as single data points. Means 
are represented with ‘x’. White; control group, Grey; Rituximab group. Time points: 0= enrolment 
sample. EP-1; End phase 1. EP-2; End phase 2. 9-36=months post enrolment All comparisons 
p=NS (Mann Whitney U test) 
B&C: Individual plots from each patient in control (B) or Rituximab-treated (C) groups. 
Time points: enrol= enrolment sample. EP-1; End phase 1. EP-2; End phase 2. V1-V10 
correspond to 9-36 months in A. 
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Supplementary Table 1 – Recruiting Centres for RituxiCAN-C4 trial. 
 
Centre Recruited patients 
West London Renal and Transplant Centre, London 17 
Guy’s & St Thomas’ NHS Foundation Trust, London 30 
St Jame's University Hospital, Leeds 2 
University Hospital, Birmingham 4 
University Hospital of Wales, Cardiff 6 
Epsom and St Helier University Hospitals Trust 1 
NHS Greater Glasgow and Clyde Trust Renal Unit, Glasgow 2 
Royal Free Hospital, London 0 
Hull Royal Infirmary, Hull 0 
Addenbrookes University Hospital, Cambridge 0 
Kent and Canterbury Hospital, Canterbury 0 
Royal Preston Hospital, Preston 0 
King’s College Hospital, London 0 
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Supplementary table 2 – Baseline characteristics of the fifty-nine patients who passed eligibility criteria to enter Phase 1. 
 
 
Included in Exploratory Analysis   
Not included in exploratory 
analysis 
Poor response to IS1 
Good 
response to 
IS (N=15) 
P2  
RCT  
Not randomised 
(N=9) 
  
   
Baseline Characteristic Control 
(N=11) 
Rituximab3 
(N=12) 
   4eGFR <20 
(N=5) 
P5 Withdrawn 
Phase 1 (N=7) 
Age (Years - Median (IQR)) 50 (15.5) 44 (24.5)  40 (7) 46 (13) *  34 (13) * 59 (18) 
Male n (%) 8 (73) 8 (67)  7 (77) 9 (60) *  3 (60) * 5 (71) 
Ethnicity n (%) 
Asian 
Black 
White 
 
1 (9) 
- 
10 (91) 
 
2 (17) 
1 (8) 
9 (75) 
  
1 (11.1) 
2 (22.2) 
6 (66.6) 
 
2 (13.3) 
2 (13.3) 
11 (74.3) 
 
* 
* 
* 
  
2 (40) 
- 
3 (60) 
 
* 
* 
* 
 
1 (14.3) 
1 (14.3) 
5 (71.4) 
Cause of renal failure 
DM 
APKD 
GN 
SLE 
HT 
Congenital6 
TIN7 
Cystinosis 
HUS 
CNI toxicity 
Unknown / not recorded 
 
- 
2 
4 
- 
- 
2 
1 
1 
- 
- 
1 
 
- 
- 
3 
1 
1 
4 
1 
1 
- 
- 
1 
  
- 
- 
3 
- 
1 
2 
3 
- 
- 
- 
- 
 
- 
- 
7 
1 
1 
1 
1 
- 
1 
18 
2 
 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
  
- 
- 
1 
- 
- 
- 
3 
- 
- 
- 
1 
 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
* 
 
1 
1 
1 
- 
2 
- 
- 
- 
- 
19 
1 
 
1 All who were eligible for RCT + the patient (G008) who developed a contraindication to Rituximab during phase 1 
2 P value, comparing good response to optimised IS (N=15) to all poor response to optimised IS, eGFR>20 (N=32) 
3 Includes 3 patients who did not receive Rituximab 
4 eGFR <20 at end of phase 1, therefore not eligible for RCT 
5 P value, comparing poor response to optimised IS, eGFR>20 (N=32) to poor response to optimised IS, eGFR <20 (n=5) 
6 Including Alports 
7 Including chronic pyelonephritis 
8 Heart transplant recipient 
9 Liver transplant recipient 
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Transplant history n ; 
Deceased 
LRD 
LURD 
Previous transplants 
0 
1 
Time from Tx (years-median (IQR)) 
HLA MM (Mean (SD)) 
Overall 
A 
B 
DR 
 
9 
2 
- 
 
9 
2 
19.6 (7.2) 
 
3.3 (1.3) 
1.3 (0.8) 
1.3 (0.6) 
1 (0.5) 
 
8 
3 
1 
 
10 
2 
5.6 (6.8) 
 
2.3 (1.6) 
0.9 (0.5) 
0.9 (0.7) 
0.5 (0.5) 
  
5 
3 
1 
 
7 
2 
14.8 (10) 
 
3 (1.3) 
1.2 (0.4) 
1.1 (0.8) 
0.7 (0.5) 
 
6 
6 
3 
 
14 
1 
16.6 (12.7) 
 
3.3 (1) 
1 (0.8) 
1.3 (0.7) 
1.2 (0.5) 
 
* 
* 
* 
 
* 
* 
* 
 
* 
* 
* 
ø 
  
2 
2 
1 
 
4 
1 
11.6 (6.9) 
 
2 (0.8) 
0.5 (0.6) 
0.75 (0.5) 
0.75 (0.5) 
 
* 
* 
* 
 
* 
* 
* 
 
 
* 
* 
* 
* 
 
5 
1 
1 
 
6 
1 
6.8 (2.5) 
 
2.4 (0.8) 
1 (0.5) 
0.6 (0.5) 
0.9 (0.7) 
HLA Ab status 
CRF (Mean (SD)) 
DSA+ n( %) 
-Class I 
-Class II 
-Both 
-NA 
DSA MFI10 
(Mean (SD)) 
 
49.4 
(37.9) 
7 (64) 
4 (36) 
2 (18) 
1 (9) 
5 (45) 
1923 
(2724) 
 
42.5 (41.1) 
6 (50) 
3 (25) 
1 (8.3) 
2 (16.7) 
6 (50) 
6822 
(7761) 
  
54.9 (39.3)11 
4 (50) 
3 (33.3) 
0 
1 (11.1) 
4 (44.4) 
4317 (7952) 
 
42.7 (37.7) 
11 (74.3) 
3 (20) 
5 (33.3) 
3 (20) 
4 (26.7) 
6758 (8998) 
 
* 
* 
* 
* 
* 
* 
* 
 
  
57.8 (34) 11 
4 (100) 
3 (75) 
1 (25) 
0 
0 
6561 
(5263) 
 
* 
* 
* 
* 
* 
* 
* 
 
 
47 (55)11 
3 (43) 
2 (29) 
0 
1 (14) 
0 
15793 (17946) 
Enrolment biopsy scores – median 
(IQR) 
C4d glom12 
Banff C4d (PTC) 
Bannf g 
Banff ptc 
Banff cg 
 
 
3 (1) 
3 (1) 
2 (1.5) 
2 (2) 
1 (1.5) 
 
 
2 (1.3) 
2 (3) 
2 (1.3) 
1 (1.3) 
2.5 (2) 
  
 
3 (1) 
2 (0) 
2 (2) 
0 (2) 
2 (2) 
 
 
3 (1) 
2 (2) 
1(2) 
1 (1) 
1 (1) 
 
 
* 
* 
* 
* 
* 
  
 
2 (1) 
2 (3) 
1 (1) 
2 (0) 
2 (2) 
 
 
* 
* 
* 
* 
* 
 
 
3 (0.5) 
2 (1.5) 
1 (1) 
1 (1) 
3 (1) 
 
10 Cumulative - includes those with DSA=0 
11 No HLA Ab data available on 3 recruits 
12 Scored as C4d PTC 
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Banff cv 
Banff ct 
Banff ci 
TA/IF (%) 
2 (1) 
2 (1) 
2 (1) 
25 (7.5) 
1 (2) 
1 (1) 
1 (1) 
25 (21) 
1 (1) 
1 (1) 
1 (1) 
25 (15) 
1.5 (1) 
1 (1) 
1 (1) 
20 (20) 
* 
* 
* 
* 
1 (2) 
1 (1) 
1 (1) 
25 (10) 
* 
* 
* 
* 
3 (1.5) 
1 (0.5) 
1 (0.5) 
30 (17.5) 
Baseline immunosuppression 
n (%) 
CNI 
Tac 
CsA 
Anti-metabolite 
MPA 
Azathioprine 
 
 
 
8 (73) 
4 (37) 
4 (37) 
8 (73) 
5 (45) 
3 (27) 
 
 
11 (92) 
10 (83) 
1 (8) 
11 (92) 
10 (83) 
1 (8) 
  
 
6 (67) 
5 (56) 
1 (11) 
8 (89) 
7 (78) 
1 (11) 
 
 
15 (100) 
8 (53) 
7 (47) 
14 (93) 
9 (60) 
5 (33) 
 
 
* 
* 
* 
* 
* 
* 
 
  
 
5 (100) 
3 (60) 
2(40) 
5 (100) 
4 (80) 
1 (20) 
 
 
* 
* 
* 
* 
* 
* 
 
 
7 (100) 
5 (71) 
2 (29) 
6 (86) 
6 (86) 
0 
Baseline renal function 
(Mean (SD)) 
Creatinine13 
eGFR14 
1/creat slope 
Formally deteriorating 
PCR15  (Mean (SD)) 
PCR >50 
 
 
 
183 (36) 
34.9 (8.6) 
-0.21 (0.3) 
9 (82) 
201 (206) 
8 (73) 
 
 
182 (48) 
37.3 (8) 
-0.17 (0.2) 
10 (83) 
242 (168) 
11 (92) 
  
 
189.7 (74) 
41.7 (17.7) 
-0.08 (0.13) 
4 (44) 
188 (280) 
8 (89) 
 
 
168.7 (44.8) 
38.6 (11.3) 
-0.07 (0.07) 
10 (67) 
74 (74) 
8 (53) 
 
 
* 
* 
* 
* 
† 
ø 
  
 
260.8 
(32.8) 
22.8 (1.6) 
-0.27 (0.32) 
5 (100) 
237 (138) 
5 (100) 
 
 
† 
† 
* 
* 
* 
* 
 
 
 
236.3 (37.4) 
25 (3.6) 
-0.146 (0.08) 
7 (100) 
305 (245) 
5 (71) 
 
Post-optimisation (pre-
randomisation) immunosuppression 
Tac n (%) 
MPA n (%) 
Tac level (Mean (SD)) 
 
 
10 (91) 
9 (82) 
5.9 (3.4) 
 
 
12 (100) 
12 (100) 
5.6 (2.3) 
  
 
9 (100) 
9 (100) 
4.4 (2.4) 
 
 
15 (100) 
15 (100) 
7.0 (2.2) 
 
 
* 
* 
ø 
  
 
5 (100) 
5 (100) 
4.8 (2) 
 
 
* 
* 
* 
 
 
- 
- 
- 
End Phase 2 medication16 
Tac n (%) 
Tac level Mean (SD) 
 
10 (91) 
5.9 (3.5) 
 
8 (100)19 
5 (3.2) 
        
 
13 µmol/L 
14 mls/min/1.73 m2  
15 mg/mmol 
16 In those RCT patients reaching primary EP. 
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MPA n (%) 
On ACE-I n (%) 
On ARB n (%) 
9 (82) 
6 (55) 
8 (73) 
8 (100) 
3 (38) 
6 (75) 
 
*P=NS 
†P≤0.005 
øP<0.05 
1o renal diagnosis: DM=diabetes mellitus: APKD=adult polycystic kidney disease: GN=glomerulonephritis: SLE=systemic lupus erythematosus: 
HT=hypertension: TIN=tubulointerstitial nephritis: HUS=haemolytic uraemic syndrome: CNI=calcineurin inhibitor. Tx type: LURD: living unrelated 
donor. LRD: living-related donor. HLA MM; Number of Class I (A,B) and Class II (DR) mismatches. Two patients (B003 and W007) had their 
transplants abroad and tissue typing was unavailable. HLA Ab status: CRF=calculated reaction frequency. DSA=donor specific antibody. 
MFI=cumulative median fluorescence intensity. Means are shown for whole group, including those with MFI of 0.  Enrolment biopsy scores: 
g=glomerular inflammation. ptc=peritubular capillary inflammation. c= chronic scores. TA/IF=tubular atrophy/interstital fibrosis. Immunosuppression; 
Tac = Tacrolimus; CsA= ciclosporin; MPA= Mycophenolic acid or mycophenolate mofetil. Baseline renal function: eGFR= estimated glomerular 
filtration rate (4 value MDRD). Formally deteriorating =meet criteria for deteriorating function based on analysis of 1/creatinine plot. Medication: ACE-
I= angiotensin converting enzyme inhibitor: ARB= angiotensin II receptor blocker.  
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Supplementary table 3 – individual patient biopsy features  
 
ID C4d g§ C4d ptc g ptc cg cv ct ci TA/IF% other features 
Withdrawn phase 1           
W001*Ω 2 2 2 1 3 3 1 1 20 TG on EM 
W005* Ω 1 2 1 0 1 3 1 1 15  
G004ø Ω 3 3 1 2 3 2 2 2 40  
G005ø Ω 3 3 2 3 2 3 3 3 70  
G020º Ω 3 1 2 1 3 3 1 1 30  
C006* Ω 3 1 1 2 2 1 1 1 <25  
X002† Ω 3 0 1 1 3 1 1 1 10  
Not eligible for RCT – 
good response to optimised IS           
W002†Ω 0 3 0 2 0 1 2 2 30 Chronic TMA 
W003†¥ 2 0 1 0 1 2 2 2 30  
W004ø Ω 2 1 0 0 0 2 1 1 15 PTCBMML on EM 
W009ø Ω 3 2 2 1 1 1 1 1 10  
W012ø Ω 2 2 0 1 0 2 1 1 10 PTCBMML on EM 
W013ø¥ 3 0 0 1 0 0 3 3 50 PTCBMML on EM 
W014ø Ω 3 2 1 0 2 2 1 1 10 PTCBMML on EM 
W016ø Ω 2 2 2 2 3 1 1 1 15  
G014† Ω 3 2 2 1 1 3 2 2 25  
G018ø Ω 3 1 1 1 1 2 1 1 10  
G019øΩ 3 3 1 2 1 1 0 1 10  
G022øΩ 3 3 2 2 1 2 2 2 30  
G024øΩ 0 0 2 2 3 1 1 1 20  
G030†Ω 0 0 0 3 3 - 3 3 80 No medium/larger calibre arteries to score 
C001øΩ 3 3 1 1 1 1 1 1 <25  
Not eligible for RCT – GFR<20 or 
contraindication to rituximab           
G001øΩ 2 2 1 2 2 3 2 2 40  
G006øΩ 2 3 0 2 1 2 1 1 20  
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G008øΩ 3 3 2 3 3 - 2 2 30 TG on EM. No medium/larger calibre arteries to score 
G028ø¥ 0 0 2 3 0 0 1 1 25  
B003*Ω 3 3 1 2 3 1 3 3 30  
B004ø¥ 3 0 0 0 3 0 1 1 15  
Eligible for RCT – not randomised           
W011øΩ 1 2 0 0 1 1 3 3 50  
W015†Ω 2 2 2 0 3 1 1 1 10 PTCBMML on EM 
W017†Ω 2 2 3 0 2 1 1 1 15  
B001øΩ 3 2 0 0 1 1 0 0 5 TG on EM 
G015øΩ 3 0 2 3 3 2 1 1 25 PTCBMML on EM 
G016†Ω 0 2 0 0 1 2 3 3 50 IgA deposition, no mesangial proliferation 
C002†Ω 3 3 2 1 3 0 1 1 <25  
C005øΩ 3 2 1 2 2 2 1 1 <25  
Eligible for RCT - randomised to control           
W006†Ω 3 1 2 1 2 1 1 1 20  
W008†Ω 2 0 2 0 1 2 2 2 25  
G002øΩ 3 3 0 0 3 2 2 2 30 Chronic TMA 
G007øΩ 3 3 1 2 1 0 1 1 15  
G011ø¥ 3 3 0 2 0 2 2 2 30  
L001†Ω 1 1 0 0 1 1 3 3 50 PTCBMML on EM 
G013†Ω 3 3 2 2 2 2 1 2 25 t2 
G027øΩ 0 0 2 0 3 0 1 1 10 TG and PTCBMML on EM 
X001øΩ 3 3 2 2 3 3 2 2 30  
G023øΩ 2 2 2 2 1 3 2 1 30  
C003øΩ 3 3 1 2 1 1 1 1 <25  
Eligible for RCT - randomised to Rituximab           
W010øΩ 2 2 3 0 3 1 1 1 15  
G003øΩ 3 3 3 1 3 2 1 1 20  
G009†Ω 3 3 3 3 3 - 1 1 15 No medium/larger calibre arteries to score 
G010øΩ 3 3 2 3 3 - 2 2 40 No medium/larger calibre arteries to score 
G012øΩ 3 0 3 2 2 3 3 3 60  
G017†Ω 2 2 3 1 3 1 2 2 40  
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B002†¥ 3 0 0 0 1 0 1 1 25 IgA deposition, no mesangial proliferation 
L002ø¥ 3 3 1 1 0 0 1 1 25  
G025øΩ 3 0 2 2 3 3 2 2 50 t3 i3 v0 
W007†¥ 1 2 1 1 0 2 2 2 40  
G029†Ω 0 0 2 3 1 0 1 1 25  
C004†Ω 1 1 2 1 1 0 0 0 0  
§ Glomerular C4 scored as for PTC. Where score is 2, C4d staining affected 25-50% of capillaries 
Enrolment DSA status: *not known; † negative; Ø positive 
BANFF 13: Ω meet histological criteria ¥ do not meet histological criteria. 
TG: transplant glomerulopthy; EM: electron microscopy; PTCBMML: peritubular capillary basement membrane multilayering; TMA: thrombotic microangiopathy. 
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Supplementary table 4: Per protocol analysis for primary outcomes at primary and secondary EPs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Estimates extracted from models at 4,8,20 and 32 months post-baseline respectively to approximately match pre-specified timepoints.  
1Estimated using a longitudinal linear mixed-effects model, with 4 arms of the study modelled together (including the 2 observational non-randomised 
arms) and randomised comparisons extracted using post-estimation methods. All available post-baseline (time 2, end of phase 1) observations 
included with a random intercept to account for dependency of repeated measurements, adjusting for baseline (time 2) and enrolment (time 1) values 
and randomisation stratifier. Time treated continuously with observed time of measurements used. A treatment x time interaction was included in the 
model. A quadratic term for time was included in the model to account for non-linearity over time. Model estimated using restricted maximum 
likelihood (REML) estimation, with missing outcomes assumed to be missing at random. 
2Estimated the same way as for the 1/Creatinine slope outcome but with bootstrapped bias-corrected CIs (1000 repetitions) reported as residuals 
were non-normal. 
3Estimated the same way as for the 1/Creatinine slope outcome but using generalisation to binary data (mixed-effects logistic regression) to estimate 
odds ratios, not including the randomisation stratifier and time 1 and time 2 observations as covariates for convergence and with robust option for 
standard errors. 
 
  
Outcome/ 
Timepoint*  
3 - 5 months post-
randomisation 
12 months post-
enrolment 
24 months post-
enrolment 
32 months post-
enrolment 
Estimated mean difference: Rituximab versus Control (95% CI) 
1/Creatinine slope1 0.14 (-0.02, 0.31) 
SE=0.08 p=0.087 
0.14 (-0.02, 0.30) 
SE=0.08 p=0.08 
0.13 (-0.03, 0.28) 
SE=0.08 p=0.111 
0.11 (-0.08, 0.30) 
SE=0.1 p=0.244 
Protein: Creatinine 
Ratio (PCR)2 
4.00 (-135.93, 
131.49) 
SE=69.59 p=0.954 
24.15 (-111.21, 
162.00) 
SE=71.93 p=0.737 
84.60 (-57.73, 
256.79) 
SE=117 p=0.472 
145.05 (-37.70, 
390.15) 
SE=184 p=0.431 
 Estimated odds ratio: Rituximab versus Control (95% CI, p-value) 
Formal binary 
criteria for 
deterioration3 
0.31 (0.01, 7.13) 
SE=0.5 p=0.464 
0.33 (0.02, 5.97) 
SE=0.49 p=0.456 
0.42 (0.01, 13.48) 
SE=0.75 p=0.626 
0.53 (0.001, 107.38) 
SE=1.44 p=0.816 
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Supplementary table 5 – Adverse events organised either according to events seen in RCT (top rows), or by events seen after optimisation of IS 
(bottom rows). 
 
Group Systemic Infections 
Cardio-
vascular 
Respir-
atory 
Gastro-
intestinal 
Genito-
urinary 
Endocrine 
/Metabolic 
Haemato-
logical 
Musculo-
skeletal 
Neuro-
logical 
Dermato-
logical Allergic 
Ear 
Nose 
Throat 
IMP-
related Total 
RCT-Control               
Neoplastic - - - - - - - - - 3 - - - 3 
Infective – suspected 
Infective – no diagnostic doubt 
1 
1 - 3 2 (2) 
1 
3 - - - - 
- 
3 - - - 
7(2) 
7 
Non-IMP drug-related - 1 - 1 - - - - 2 - - - - 4 
Other - 2 1 5 (2) 1 (1) 2 (2) 6 (1) 1 - 1 - - - 19 (6) 
Total 3 3 4 8 (4) 5 (1) 2 (2) 6 (1) 1 2 6 0 0 0 40 (8) 
RCT-Rituximab               
Neoplastic - - - 1 (1) - - - - - 1 - - 1 (1) 2 (1)* 
Infective – suspected 
Infective – no diagnostic doubt 1 - 
5¶ (2) 
2# (2) - 
- 
2§ (1) - - 
- 
1 - 
1 
5 (1) - - 
- 
3 (2) 
7 
10 
(4)* 
Non-IMP drug-related - - - - - 1 - - - 1† - - - 2 
Other - 1 - 6¶ (1) - 4 (1) 4 (1) 4 4 (1) 2 - -  25 (4) 
Total 1 1 7 (2) 7 (2) 2 (1) 5 (1) 4 (1) 5 4 (1) 10 (1) 0 0 4 46 (9)* 
               
               
Good response to optimised IS 
(PCR<50, stable creatinine)               
Neoplastic - - - - - - - - - - - - - 0 
Infective 2 (2) - 8 1 6 (1) - - - - 15 (3) - - - 32 
Non-IMP drug-related - - - 4 (1) - 1 - - - 1 (1) - - - 6 
Other - 8 (3) 1 (1) 7 (2) 4 (1) 5 4 1 1 3 (1) - 2 - 36 
Total 2 8 (3) 9 (1) 12 (3) 10 (2) 6 4 1 1 19 (5) 0 2 0 74 
Poor response to optimised IS 
(PCR>50 ± deteriorating 
creatinine, eGFR>20)¥ 
              
Neoplastic - - - 1 (1) 1 - - - - 4 - - 1 (1) 6 (1)* 
Infective 4 - 14 (2) 2 (2) 6 (1) - - 1 - 10 (2) - - 3 (2) 37 (6)* 
Non-IMP drug-related - 1 - 1 - 1 1 - 2 2 1 - - 9 
Other - 8 (4) 1 15 (5) 1 (1) 8 (3) 10 (2) 7 4 (1) 5 - - - 59 (16) 
Total 4 9 (4) 15 (2) 19 (8) 8 (2) 9 (3) 11 (2) 8 6 (1) 21 (2) 1 0 4 (3) 111 (23*) 
P values NS NS NS NS NS NS NS NS NS NS NS NS NS NS 
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AEs meeting criteria for SAE are in (parentheses) 
*The adverse events classified as Investigational Medical Product (IMP)-related are only counted once in the total. 
¶ includes a chest infection and non-drug-related diarrhoea in a patient who withdrew in phase 2 before receiving Rituximab. 
# includes severe pulmonary oedema due to acute aortic valve rupture in a patient, which contributed to patient death. 
§includes a UTI in a patient who withdrew during phase 2 post-rituximab 
† includes angioedema secondary to Ramipril in a patient who did not receive rituximab 
¥ this group includes the patients in the control and rituximab-treated groups 
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Supplementary Table 6: Changes in Donor specific antibody (DSA) Median Fluorescence intensity (MFI) in patients included in the exploratory study 
Recruit number Specificities of DSA  (DSA with MFI<2000) Enrol End Phase 1 
End 
Phase 
2 
Phase 3 
 End Year  1    
End 
Year 2    
End 
Year 3 
Good response to optimisation of IS               
W002 None* 0 -  0 0 0 0 0 0 0 - - - 
W003 CW4 0 1814  0 881 0 0 2377 1758 0 0 0 0 
W004 B44, DR53 (Cw2) 7280 15587   11214 16552 17270 14228 11724 10683 16055 12984 18644 16791 
W009 B44, DR53, DQ8 (B60, Cw5) 6271 3311  3049 14124 12343 0 13103 11486 0 0 10870 - 
W012 DQ3 15000 10000  17330 10872 16088 17642 13903 16350 - - 8763 - 
W013 (A3) 400 0  0 - 0 0 - - - - -  
W014 DQ4 (B60) 14805 12133  12710 15772 10932 15160 11220 14179 - 9756 15010 - 
W016 (B35, DR1) 750 695  981 - - - - - - - - - 
G014 A2 (A1) 0 -  0 0 0 0 0 4214 3450 4052 0 0 
G018 DQ7 9655 0  7241 8255 9627 5830 8532 6546 5322 6260 8642 8529 
G019 B44, Cw5 6526 5833  7428 3969 6440 5886 2468 7331 2010 - 2915 1893 
G022 DQ6 4898 0  0 0 0 - 0 - 4277 0 - - 
G024 A28, A11, B14, DQ3 33494 46868  49299 32692 46397 33556 - - - - - - 
G030 DQ3 0 9867  12090 0 - - - - - - - - 
C001 DR13, DR52 (A3, B61) 3200 10132  - - - - - - - - - - 
Poor response to optimisation of IS               
W006 (RCT-C) (B37) 0 0 0 0 0 0 0 0 0 0 0 1908 - 
W008 (RCT-C) None 0 0 0 0 0 0 0 0 0 0 0 0 - 
G002 (RCT-C) A1, (Cw7) 2784 2199 - 0 2837 - - - - - - - - 
G007 (RCT-C) A2, DR12, (Cw7) 8845 15450 13682 - 10126 11413 16469 20864 14495 - - - - 
G011 (RCT-C) DR17* 1601 8568 - - - - - - - - - - - 
L001 (RCT-C) None* 0 0 - - - - - - - - - - - 
G013 (RCT-C) None* 0 0 0 0 0 0 0 0 0 0 0 0 0 
G027 (RCT-C) (B8)* 750 1020 - 750 - 800 - - - - - - - 
X001 (RCT-C) B7 8714 14850 16049 - 12658 - - 16140 - - - - - 
G023 (RCT-C) DR53* 3591 4426 4500 - - - - - - - - - - 
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C003 (RCT-C) A2 3592 - - - - - - - - - - - - 
Given Rituximab               
W010 (RCT-R) A2, DR53 6617 0 0 8019 0 0 - - - - - - - 
G003 (RCT-R) B8 15246 10358 13934 13335 - 9486 - 12518 9076 10996 12846 10384 8979 
G009 (RCT-R) None* 0 0 - - - - - - - - - - - 
G010 (RCT-R) A1 (B8) 14010 6632 - - - - - - - - - - - 
G012 (RCT-R) A2, A23, DQ2 (B44) 20711 12278 16573 15570 10999 8277 14028 16279 12566 - - - - 
G017 (RCT-R) Cw4 0 0 2693 2542 1739 0 1200 - - - - - - 
B002 (RCT-R) None 0 0 - 0 - 0 0 - 0 - 0 - - 
L002 (RCT-R) A1 12460 10717 - - 8697 10010 12586 10380 9417 - - - - 
G025 (RCT-R) DR53, DQ7 12824 0 4308 14265 - 16972 15402 6113 - - - - - 
W007 (RCT-R†) None 0 0 - - - - - - - - - - - 
G029 (RCT-R†) DR53 0 1656 - 0 2147 - - - - - - - - 
C004 (RCT-R†) None 0 - - - - - - - - - - - - 
G008 (NR) A11, Cw12 (A32, B18,  B52, DR7) 22867 24630  20992 - - 20655 - - - - - - 
W011 (NR) A2 3912 9590  12084 11096 11612 15616 19752 13951 13066 - 12255 5055 
W015 (NR) DQ2 0 4067  3813 - - - - - - - - - 
W017 (NR) B7 B60 0 0  0 0 10481 0 0 0 0 0 - - 
B001 (NR) A1 (DQ8) 450 4240  3801 - 6168 - 17856 - - 4904 12435 14193 
G015 (NR) DR14 (Cw2, DR52) - 4192  3185 2667 2315 3254 3039 6414 9100 3749 7396 - 
G016 (NR) (DQ6) 0 1603  1220 0 0 1993 1855 0 0 400 - - 
C002 (NR) none 0 -  - - - - - - - - - - 
C005 (NR) B40 7307 -  - - - - - - - - - - 
Specificities in (parentheses)  = MFI <2000:  
RCT-C – randomised to control group 
RCT-R – randomised to rituximab group: † Not given rituximab 
NR – not randomised 
G002 – Cw7 only at enrol and end year 1. G007 - all separate DSA intermittently positive throughout. G010 - B8 present at enrolment only. G012 – DQ2 only at enrol, B44 only during 
phase 3 year 2.  
W004 – DR53 at all time points, B44 detected at EP-1 and T6  
W009 – DR 53 at enrol, EP-1, T1. DQ8 at T2, T3, T5, T6 and T9. B44 only at T9. T8 No DSA. 
* No donor DQ typing available. Linkage disequilibrium suggests there may be potential DSA to donor DQ. 
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Supplementary Table 7 – Dynamic changes in ELISPOT patterns, in 27 patients in the exploratory study who had viable and interpretable enrolment samples, 
with ≥2 at or beyond end of phase 2.  (Refer to main table 4 and figure 5D for how these patterns relate to trends in eGFR) 
 Enrolment End Phase 1 9/12 (or End phase 2) End year 1 End Year 2 End year 3 
ID Anti-donor response Anti-donor response Anti-donor response Anti-donor response Anti-donor response Anti-donor response 
 
No Non-regulated B-
dependent anti-donor 
IFNg at or beyond phase 
2 
     
W003 (GRO) No response No response No sample No response No response No response 
W012 (GRO) No response CD19+ Regulated B-dependent* No sample No response 
Regulated B-
dependent† No response 
B001 (NR) No response No response No sample No response No sample No response 
W014 (GRO) No response No response No sample No response No response No response 
G014 (GRO) No response No response No sample No response No response No response 
W002* (GRO) Unreg B-dependent No response No sample CD25+ Regulated B-dependent No response Graft failure 
W009 (GRO) No response No sample No sample No response No response Regulated B-dependent† 
W011 (NR) No response No response No sample CD19+ B-regulated Regulated B-dependent† CD19+ B-regulated 
G018 (GRO) No response No response No sample No response No response No response 
X001 (RCT-C) No response No response No response No response No response No sample 
G007 (RCT-C) No response No response No response No response No response No sample 
G024 (GRO) No response No response No sample CD25+ CD19+ B-regulated* No response No sample 
G015 (NR) No response No response No sample No response CD25+ Regulated B-dependent Withdrawn 
W006 (RCT-C) Unreg B-dependent CD19+ Regulated B-dependent* CD19+ B-regulated No response No response No response 
G013 (RCT-C) CD25+ Regulated B-dependent No response No response 
CD25+ CD19+ B-
regulated* No response No response 
W008 (RCT-C) CD25+ Regulated B-dependent No response 
CD25+ CD19+ B-
regulated* No response No response 
CD25+ CD19+ B-
regulated* 
G022* (GRO) Unreg B-dependent No response No sample CD19+ B-regulated No response CD25+ Regulated B dependent 
L002 (RCT-R) No response CD25+ Regulated B-dependent No response No sample No response Graft Failure 
G012 (RCT-R) CD25+ Regulated B-dependent No response No response No response No response Withdrawn 
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G003 (RCT-R) CD19+ B-regulated CD25+ Regulated B-dependent No response No response No response No response 
B002 (RCT-R) Regulated B-dependent† 
Regulated B-
dependent† No response No sample 
CD25+ Regulated B-
dependent No response 
 
At least 1 sample 
showing non-regulated 
B-dependent anti-donor 
IFNg at or beyond phase 
2 
     
G016 (NR) Unreg B-dependent No response No sample Unreg B-dependent CD25+ CD19+ B-regulated* 
CD25+ Regulated B-
dependent 
W017 (NR) No response Regulated B-dependent† No sample CD19+ B-regulated Unreg B-dependent Graft failure 
G002 (RCT-C) Unreg B-dependent CD25+ CD19+ B-regulated* No response Unreg B-dependent Graft Failure  
W010 (RCT-R) Unreg B-dependent CD19+ B-regulated Regulated B-dependent† Unreg B-dependent Graft Failure  
G025 (RCT-R) Unreg B-dependent No response Unreg B-dependent No response No response No response 
G017 (RCT-R) CD25+ Regulated B-dependent Unreg B-dependent No response No sample Unreg B-dependent No sample 
 
 
W002* and G022* - given Rituximab outwith the trial protocol in year 2. 
GRO – good response to optimised IS 
RCT-C – randomised to control group 
RCT-R – randomised to rituximab group 
NR – not randomised 
CD25+ regulated B-dependent – Evidence of B-dependent anti-donor responses only when CD25+ cells depleted (shaded blue) 
CD19+ Regulated B-dependent*– Evidence of Bdep when CD25+ present, but Breg when CD25+ absent (shaded blue) 
Regulated B-dependent*† – Evidence of CD25+ or CD19+ regulation at one antigen dose, but B-dependent responses at a second antigen dose (shaded blue). 
CD19+ B-regulated – Evidence of anti-donor reactivity when CD19+ cells depleted, when CD25+ cells present (shaded green) 
CD25+ CD19+ B regulated* – Evidence of Breg when CD25+ absent, Suppression of all anti-donor reactivity when CD25+ present (shaded green) 
Unregulated B-dependent – Anti-donor activity reduces (≥20%) when B cells depleted. No evidence of regulation (shaded orange) 
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Supplementary table 8: Dynamic ELISPOTS from the 16 remaining patients in the exploratory study. 
 Enrolment End Phase 1 9/12 (or End phase 2) End year 1 End Year 2 End year 3 
ID Anti-donor response Anti-donor response Anti-donor response Anti-donor response Anti-donor response Anti-donor response 
L001 (RCT-C) CD19+ B-regulated No response No sample No sample Graft failure  
G027 (RCT-C) No response No response No sample No response No sample Withdrawn 
G023 (RCT-C) Unreg B-dependent CD25+ Regulated B-dependent No response Withdrawn   
C003 (RCT-C) No response No samples No sample No sample No sample No sample 
G009 (RCT-R) No response No response Graft failure    
G010 (RCT-R) No response No response No response Graft failure   
W004 (GRO) Non-viable Non-viable No sample Reactive – not interpretable further No response No response 
W013 (GRO) No response Unreg B-dependent No sample No response Withdrawn  
W016 (GRO) No response No response No sample Withdrawn   
G030 (GRO) No response No response No sample No response No sample Graft failure 
C001 (GRO) No response No response No sample No response No sample Graft failure 
G008 (NR) No response No response No sample No response Graft Failure  
W015 (NR) No response No response No sample Withdrawn   
C002 (NR) CD19+ B-regulated No sample No sample No sample No sample No sample 
C005 (NR) No response No sample No sample No sample No sample No sample 
G029 (RCT-R†) No response No response No sample CD19+ B-regulated Withdrawn  
 
These samples are included in the analyses contained in main table 2 and 3, but not in the analysis included in main table 4 and figure 5D. 
GRO – good response to optimised IS 
RCT-C – randomised to control group 
RCT-R – randomised to rituximab group: † Not given rituximab 
NR – not randomised 
CD25+ regulated B-dependent – Evidence of B-dependent anti-donor responses only when CD25+ cells depleted (shaded blue) 
CD19+ Regulated B-dependent*– Evidence of Bdep when CD25+ present, but Breg when CD25+ absent (shaded blue) 
Regulated B-dependent*† – Evidence of CD25+ or CD19+ regulation at one antigen dose, but B-dependent responses at a second antigen dose (shaded blue). 
CD19+ B-regulated – Evidence of anti-donor reactivity when CD19+ cells depleted, when CD25+ cells present (shaded green) 
CD25+ CD19+ B regulated* – Evidence of Breg when CD25+ absent, Suppression of all anti-donor reactivity when CD25+ present (shaded green) 
Unregulated B-dependent – Anti-donor activity reduces (≥20%) when B cells depleted. No evidence of regulation (shaded orange) 
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1 STUDY SYNOPSIS 
 
Title of clinical trial A randomised controlled trial of anti-CD20 in 
C4d+ chronic allograft nephropathy 
Sponsor name King’s College London 
Eudra CT number for proposed trial 2006-002330-38 
Medical condition or disease under 
investigation 
C4d+/- chronic allograft nephropathy (CAN) 
Purpose of clinical trial Evaluate the effectiveness of rituximab in 
C4d+/- CAN 
Primary objective To determine whether anti-CD20 therapy 
can stabilise or improve renal function 
and/or proteinuria in patients with C4d+/-, 
chronic (humoral) rejection in whom 
standard therapeutic approaches have 
failed. 
Secondary objective (s) To compare patient and graft survival 
between control and rituximab-treated 
groups 
To evaluate the adverse effect profile of 
rituximab in this group 
To correlate changes in circulating B cell 
numbers, anti-HLA and non-HLA Ab profiles 
and titre with responses to standard therapy 
and / or rituximab 
To correlate changes in T cell 
responsiveness to alloantigens with 
responses to standard therapy and / or 
rituximab 
 
Study Design  Prospective, randomised, two arm, open-
labelled 
Study Endpoints 1˚ - Rate of deterioration in renal function, 
defined by slope of reciprocal creatinine 
plot, on samples taken 3-5 months post-
randomisation. 
-Change in degree of proteinuria, where 
present, at 3-5 months post-randomisation 
2˚ endpoints, determined at 3-5 months 
post-randomisation and at 1, 2 and 3 years 
post-recruitment are; 
•Rate of deterioration in renal function, 
defined by slope of reciprocal creatinine 
plot, determined by analysis of samples 
taken since previous assessment. 
•Patient survival 
•Graft survival 
•Incidence of culture positive infection  
•Incidence of malignancy 
•Degree of proteinuria  
•Changes in circulating CD20+ cells in 
peripheral blood 
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•Changes in anti-graft Ab titres, (measured 
every 3 months) 
• Changes in T cell responsiveness to 
alloantigens (measured every 3 months). 
Sample Size A two group chi-squared test with a 0.05 
one-sided significance level will have 80% 
power to detect the difference between 70% 
stabilisation on rituximab and 20% 
stabilisation in the control group if 15 
patients reach the primary endpoint (i.e. 30 
patients complete phase 2). It is anticipated 
that approximately 25% of patients recruited 
to the run-in period will enter the 
randomisation process that signals the 
beginning of phase 2. Therefore, 
approximately 120 patients will be enrolled 
into the study. In addition, in those 
participants that received a living donor 
kidney, these donors will be approached to 
provide up to 5 samples of blood to help 
with the in vitro analyses. 
Summary of eligibility criteria Male or female renal allograft recipients 18-
70 years of age 
>6/12 post-transplantation  
Either deteriorating allograft function on 
reciprocal creatinine plot or significant 
proteinuria or both. 
C4d+/- CAN on renal allograft biopsy 
Investigational medicinal product 
and dosage 
Rituximab, 1g on day 0 and 1g on day 14 
Active comparator product(s) None 
Route(s) of administration  Intravenous infusion 
Maximum duration of treatment of a 
subject 
14 days with rituximab.  The treatment arms 
of the study, including optimisation period, 
formal run-in and post-randomisation phase 
lasts for 10 months post-recruitment. 
Procedures: Screening & 
enrolment 
Potentially eligible patients will be identified 
by screening renal allograft biopsies 
performed for ‘creeping creatinine’ and/or 
proteinuria.  Eligible patients will be asked 
for informed consent prior to enrolment. 
  Baseline In addition to routine tests, blood will be 
obtained for anti-HLA and non-HLA antibody 
analysis and for peripheral blood 
mononuclear cell (PBMC) purification. 
  Treatment period The treatment period comprises a 3-month 
run-in period during which the patient will be 
on stabilised optimal immunosuppressive 
therapy.  This period will be preceded by up 
to 2 months to allow tailored-optimisation for 
that individual.  During the formal run-in, 
patients will be reviewed at least six times in 
their normal transplant clinic appointments 
for routine blood biochemistry, full blood 
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count and urine analysis.  At the end of the 
run-in period, further blood will be taken for 
anti-graft antibody analysis and PBMC 
purification.  Those patients in whom 
allograft function stabilises and/or 
proteinuria improves will have normal 
transplant clinic follow-up appointments and 
have blood taken for further anti-graft 
antibody and PBMC purification up to every 
3 months for 3 years.  Those with continued 
deterioration in either allograft function or 
persisting or worsening proteinuria will be 
eligible for randomisation if they consent to 
phase 2 of the study. 
These patients will be reviewed during their 
normal transplant clinic appointments until 
the primary end-point and will need to have 
at least 6 routine blood biochemistry, full 
blood count and urine analysis during the 
final 3 months of this period, post-
randomisation.  At the primary end-point, 
further blood will be taken for anti-graft 
antibody analysis and PBMC.   
 End of Study Follow up will continue for 3 years, with 
blood taken for anti-graft antibody analysis 
and PBMC purification every three months  
Procedures for safety monitoring 
during trial 
Regular patient interviews and examination, 
routine haematological and biochemical 
analyses. 
Serious adverse events will be reported and 
forwarded to the sponsor, MHRA, REC and 
Roche as appropriate 
The King’s transplant research committee 
will discuss the trial and any safety concerns 
at their regular three monthly meetings. 
The external data monitoring committee will 
review data at 3 points, following 
randomisation of 10, 20 and 30 patients. 
Criteria for withdrawal of patients on 
safety grounds 
Serious adverse effects related to rituximab 
infusion 
Regulatory submissions on safety 
grounds 
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2 STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N=15 
N=15 
Identify 
patient 
population 
Randomisation 
Failed run-in 
Still meet entrance criteria 
 
Passed run-in 
Now fail to meet  
entrance criteria 
 
Continue 
optimal 
standard care 
Anti-CD20 
•2 x 1g doses 
day 1 and 14 
End of run-in 
Run-in period of 
optimal standard 
therapy 
PHASE 3 
Formal study observations every 3 
months to 3 years post - recruitment 
PHASE 1 
0-2 months to optimise 
3 months optimal therapy 
 
1˚ Endpoint 
Consent 
3 months assessment period 
N=approx. 120 
N=estimated 90 
N=30 
3-5 months 
post- 
randomisation 
Rituximab to be administered 
within first month 
1 month post-rituximab to stabilise 
3 months assessment period 
 
Consent 
PHASE 2 
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4 Introduction 
4.1 Background 
The rate of acute renal allograft loss over the last decade has improved significantly with newer 
immunosuppressive drugs, but loss due to chronic allograft nephropathy (CAN) remains an important 
problem; - by 10-12 years after transplantation, approximately 50% of patients have returned to 
dialysis. Premature allograft failure is now one of the leading causes of end stage renal disease, so 
that, for instance, almost 5000 patients return to dialysis each year in the USA (3). Although multiple 
factors contribute to the aetiology of CAN (4), a significant proportion of cases have evidence of 
ongoing immunologically-mediated damage, or ‘chronic rejection’ (CR). This may be manifest in 
glomeruli (transplant glomerulopathy), peritubular capillaries (PTC) or arteries (transplant 
arteriopathy).  The arteriopathy of CR is characterised by neointimal expansion and remodelling, 
leading to progressive obliteration of the vessel lumen and chronic ischaemia. The pathophysiology 
of CR is complex and incompletely understood, but a potentially important factor in a sizeable 
proportion of patients is that they develop anti-HLA antibodies (Ab) prior to suffering graft 
deterioration (5, 6). If these Ab are donor (graft) specific Ab (DSA), they may bind donor endothelial 
cells (EC) and if complement-fixing, mediate organ damage in a similar way to acute humoral 
rejection (7, 8).  
The criteria for formal definition of chronic humoral rejection (CHR) includes the detection of 
circulating DSA in the peripheral blood (9), although by this definition, a significant proportion of 
patients with antibody-mediated pathology probably go undetected.  This is because it has been 
hypothesised that most high affinity DSA will be deposited within the graft vasculature and DSA 
within the circulation will only be detected once the antigen binding sites in the graft have been 
saturated, which will occur only in those generating significant quantities of Ab (5).  Although DSA 
bound within the graft are difficult to detect directly by conventional immunohistology, indirect 
evidence of their deposition, if they are complement-fixing, is provided by finding complement 
component C4d deposition on graft PTC EC (9).  C4d deposition correlates strongly with ongoing 
anti-HLA Ab-mediated CHR (10, 11).   Therefore, for the purposes of this study, CHR will be defined 
primarily on the basis of positive PTC C4d staining.  By this definition, CHR probably accounts for 
1/3rd of all grafts lost to CAN (11). 
There is no established treatment for CHR. Theruvath et al reported short-term stabilisation of renal 
function in 3 out of 4 patients after establishing them on tacrolimus, mycophenolate mofetil (MMF) 
and prednisolone, a regime based on a one shown to have efficacy in acute humoral rejection (12). 
Although there are several problems with this approach, the most important is that it only appears to 
be effective in about 75% of patients, and 25% to continue to reject their grafts. This has been our 
experience at the Hammersmith, using a similar approach (without steroids), where we have achieved 
short-term stabilisation of function in a similar proportion of a small cohort of patients.  
At the moment, in these patients who continue to deteriorate, we administer another drug called 
rituximab (brand name Mabthera), because there are good scientific and clinical reasons to believe 
that it may be beneficial in patients who have evidence of this type of antibody-mediated damage.  
Rituximab is a chimeric mouse/human monoclonal antibody specific for CD20, a marker found 
only on certain types of B cells.  It is licensed for use in B cell lymphomas, because it is known to 
deplete B cells and has a relatively benign side effect profile, characteristics which have helped it to 
quickly become an established therapy for these conditions.  
Our experience to date, having administered it to 4 patients, suggests that graft function stabilises in 
approximately 50% of patients given rituximab.  However, we have no firm evidence that these 
50% are stabilising because of the rituximab, or whether they would have stabilised anyway 
(because they needed more time on ‘optimal immunosuppression’), nor whether the use of 
rituximab is going to lead to the development of any longer term problems. Hence, we have 
designed this study to answer three questions.  First, is it the rituximab that stabilises kidney 
function or will stabilisation occur after staying on optimal treatment for a longer period of time.  
Second, is the use of rituximab associated with any short, medium and longer-term adverse effects 
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compared to staying on optimal immunosuppression.  Finally, can we monitor the way the immune 
system responds after each of these treatment approaches, not only to try and understand how the 
treatments may be working, but also to develop tests that might predict responsiveness to the 
different types of therapy? 
 
4.2 Clinical Data 
4.2.1 Efficacy 
Rituximab was first approved by the FDA in 1997 for treatment of relapsed or refractory indolent 
CD20-positive non-Hodgkin’s lymphoma (NHL) and has now been shown to be efficacious and 
well-tolerated in the treatment of NHL and chronic lymphocytic leukaemia with evidence of 
efficacy in other B cell diseases such as multiple myeloma, Waldenstrom’s macroglobulinaemia 
and post-transplant lymphoproliferative disease (PTLD). Over half a million patients have received 
rituximab, which means that there is now a well-established safety profile for its use in B cell 
malignancies for first line and maintenance therapy, when used as monotherapy and in combination 
with both chemotherapy and immunotherapy.  
 
More recently, rituximab has been used as treatment in autoimmune diseases such as rheumatoid 
arthritis (RA). The first open-label study used rituximab in combination with cyclophosphamide 
and steroids in refractory RA in five patients (13). It reported dramatically improved clinical status 
that was maintained at one year.  Since then a double-blind randomised controlled trial involving 
161 patients has demonstrated the efficacy of combination therapy with rituximab and methotrexate 
(MTX) or cyclophosphamide over MTX alone (14).  In this study, where the primary endpoint was 
achievement of an ACR (American College of Rheumatology) response of 50 at 24 weeks, 
rituximab added to MTX delivered a response in 43% whereas rituximab added to 
cyclophosphamide delivered a response in 41%, both of which were statistically significantly 
different to the 13% who responded to MTX alone. There was profound B cell depletion in patients 
treated with rituximab, a rapid decline in rheumatoid factor levels, but no significant change in 
immunoglobulin levels and no significant difference in infection rates between the treatment arms.  
 
Rituximab has also been used in systemic lupus erythematosus (SLE), in which B cells are know to 
play an important role in disease pathogenesis (15, 16). As yet, there have been no randomised 
controlled trials or head-to-head comparison with conventional immunosuppression in SLE.  An 
early phase I/II study used rituximab as monotherapy at low, medium and full-dose (2 doses of 
1000mg 2 weeks apart) in 17 patients (17). This preliminary study demonstrated that in the 11 
patients who had good B cell depletion, there was a significant improvement in symptoms and in 
their Systemic Lupus Activity Measurement Score. Those who did not achieve good B cell 
depletion did not improve clinically and were also at higher risk of developing human anti-chimeric 
antibody. 3 patients had serious infections, although these were not felt to be directly related to the 
treatment with rituximab, but rather to the pre-existing leukopenia of these patients. Another early 
open label study conducted at University College London in 6 patients who had not responded to 
conventional treatment for SLE showed that use of medium dose rituximab (2 doses of 500mg) in 
combination with cyclophosphamide and prednisolone was well-tolerated with no significant 
adverse events and associated with a sustained clinical improvement (18). 
 
In the context of renal transplantation, rituximab has been reported to successfully treat acute 
humoral rejection refractory to conventional treatment and to reduce the titres of anti-blood group 
or anti-HLA antibodies in patients prior to transplantation (19).  These data have all come from 
relatively small groups of patients.  
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4.2.2 Safety and tolerability 
The tolerability and safety of rituximab in haematological malignancy has been well-described in 
the pivotal phase III study in 166 patients with indolent lymphoma (20) and in patients with other B 
cell malignancies (21-23).  
The most common adverse events were infusion-related reactions, with the majority of patients 
experiencing mild to moderate symptoms on the first dose, most frequently fever (43%), chills 
(28%), nausea (18%) and headache (14%) within 2 hours of the infusion. The frequency and 
severity are reduced by premedication with paracetamol and an antihistamine given 30 to 60 
minutes prior to the infusion. These minor reactions remit rapidly on temporary discontinuation of 
the infusion, and if additional pre-medication is given and the infusion resumed at a lower rate there 
is a low risk of further reactions. In approximately 10% of patients receiving their first dose 
hypotension, bronchospasm or angio-oedema may occur, necessitating other supportive and 
symptomatic treatment. The frequency and severity of adverse events is markedly reduced on 
subsequent infusions, possibly because of a lower tumour burden. 
Severe adverse events are uncommon, with 12% of patients experiencing grade 3 severity and 3% 
with grade 4 severity. The more severe events which have been reported include pulmonary 
infiltrates, an interstitial pneumonia, acute respiratory distress syndrome and myocardial infarction / 
cardiac arrhythmias all occurring within hours of starting the infusion. These events appear to be 
the result of cytokine release syndrome, related to the rapid lysis of tumour cells. Fatalities have 
been rarely reported, with the risk of death from an infusion-related anaphylactic-type response 
(hypotension, angioedema, bronchospasm and hypoxia) of 0.04-0.07%. Those with underlying 
pulmonary or cardiac disorders are at increased risk of adverse events, and require careful attention 
to fluid balance, and a reduced infusion rate and additional monitoring may be indicated.   
 
In autoimmune disease, infusion-related reactions were less common than seen in patients with 
haematological malignancy.  So, for instance, in the double-blind placebo-controlled study of 161 
patients with RA mentioned above, 36% of patients given rituximab developed a reaction after the 
first dose compared to 30% of patients given placebo (24).  Side effects included transient 
hypotension/hypertension, pruritus, flushing, rash, fever and dyspnoea. With second and subsequent 
infusions there was no significant difference between rituximab and placebo (17% and 15%). These 
rates are significantly lower than the frequency of adverse events in the pivotal study on patients 
with indolent lymphoma in which 74% experienced an adverse event (20), which may be due to the 
lack of tumour burden and / or treatment with steroids being part of the trial protocol in the 
rheumatoid arthritis patients. 
 
4.2.3 Pharmacokinetics & pharmacodynamics 
The following is taken from the Core data sheet for MabThera 
‘Pharmacokinetic studies performed in a phase I study in which patients (N=15) with relapsed B–
cell lymphoma were given single doses of rituximab at 10, 50, 100 or 500 mg/m2 indicated that 
serum levels and half-life of rituximab were proportional to dose [26, 27]. 
In a cohort of 14 patients among the 166 patients with relapsed or chemoresistant low-grade or 
follicular non-Hodgkin’s lymphoma enrolled in the phase III pivotal trial and given rituximab 375 
mg/m2 as an IV infusion for 4 weekly doses, the mean serum half-life was 76.3 hours (range, 31.5 to 
152.6 hours) after the first infusion and 205.8 hours (range, 83.9 to 407.0 hours) after the fourth 
infusion. The mean Cmax after the first and fourth infusion were 205.6 ±59.9 µg/mL and 464.7 
±119.0 µg/mL, respectively. The mean plasma clearance after the first and fourth infusion was 
0.0382 ±0.0182 L/h and 0.0092 ± 0.0033 L/h, respectively. However, variability in serum levels 
was large. Rituximab serum concentrations were statistically significantly higher in responding 
patients than in non-responding patients just prior to and after the fourth infusion and post-
treatment. Serum concentrations were negatively correlated with tumor burden and the number of 
circulating B-cells at baseline. Typically, rituximab was detectable for 3 – 6 months after 
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administration of the last infusion (25). 
 
Distribution and elimination have not been extensively studied in patients with DLCL, but available 
data indicate that serum levels of rituximab in DLCL patients are comparable to those in patients 
with low-grade or follicular NHL following treatment with similar doses.” 
Little data is available from other patient groups.  Pescovitz reports on a single dose study in 
patients with renal failure (26), in which the half-life was significantly prolonged compared to that 
above, at up to 14 days.  In this group, Rituximab was detectable on the circulation for many 
months post-dose.  In rheumatoid arthritis, the half-life of the second dose has been reported to be 
as long as 20 days (26). 
 
4.2.4 Mechanism of action 
CD20 is a transmembrane protein found predominantly on B cells, specifically on pre-B and mature 
B cells, including malignant B cells, but not on haematopoietic stem cells, plasma cells and normal 
tissue. It is vital for B cell differentiation and proliferation. After administration, rituximab appears 
to cause loss of CD20-positive cells by antibody dependent cellular cytotoxicity, complement-
mediated lysis and by direct induction of B cell apoptosis. For the treatment of haematological 
malignancy, the standard treatment course is 4 doses over 4 weeks, following which there is 
significant depletion of B cells in peripheral blood lasting approximately 2 to 6 months, with 
gradual recovery of non-malignant B cell numbers to normal levels by 12 months. However, there 
is no reduction in the number of plasma cells, serum immunoglobulin levels are well-maintained, 
and T-cells are completely unaffected.   
It is perhaps because of this that rituximab appears not to be associated with the potentially severe 
immunosuppressive side effects associated with non-selective depleting polyclonal Ab such as anti-
lymphocyte or anti-thymocyte globulin, or the mouse monoclonal antibody OKT3.  A small 
percentage of patients (1% approx) have been described to develop human anti-chimeric Ab but not 
human anti-mouse Ab. 
 
5 RATIONALE FOR STUDY 
There is no firmly established treatment for CHR, though as indicated above, short-term 
stabilisation of renal function appears to result in 75% of patients after conversion to (or 
optimisation of) MMF and tacrolimus therapy ± prednisolone.  Of the 25% who continue to 
deteriorate, our experience suggests that rituximab can stabilise function in approximately half of 
these. 
Although the use of rituximab in this group is rational, we have no firm evidence of efficacy in this 
group of patients and no clear idea about whether it’s use may be accompanied by a increased risk 
of acute viral, bacterial or fungal infection or malignancy.  This study will address these two points.  
Additionally, we will perform studies to try and understand how rituximab may be working and to 
correlate responses to optimal immunotherapy or rituximab with assays of immune responsiveness 
and histological appearances. 
Our ultimate aim is to establish the basis for using rituximab as a first-line therapy in this condition. 
If this study confirms that it is successful at stabilising function in those patients who fail standard 
therapy, with an acceptable safety profile, this would pave the way for earlier use of rituximab in 
this group of patients. 
 
6 TRIAL OBJECTIVE AND PURPOSE 
 
Primary Aim; To establish the efficacy of rituximab at stabilising renal function and/or reducing 
proteinuria in patients with CHR who have failed to stabilise on standard, optimal therapy 
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Secondary Aims; 
To compare patient and graft survival between control and rituximab-treated groups 
To document the adverse effect profile of rituximab in this group 
To correlate laboratory parameters with responses to standard therapy or rituximab 
 
7 TRIAL DESIGN 
7.1 Statement of design 
 
This is to be an open, controlled randomised study.  All eligible patients will be recruited over a 
three year period, and initially undergo a run-in period during which time standard therapy will be 
optimised (0-2 months) followed by 3 months on fully optimised therapy.  At the end of the run-in, 
graft function and degree of proteinuria will be re-assessed and patients who still meet the criteria 
for entrance into the study (i.e. those that still have deteriorating function or persisting or worsening 
proteinuria) will be randomised to either remain on standard therapy only, or to receive rituximab.  
For those receiving rituximab, the two infusions will be given within one month of randomisation 
and the formal 3-month analysis period will begin one month after the last dose of rituximab.  For 
those randomised to stay on standard therapy, the formal 3-month analysis period will begin on the 
day of randomisation.  For both groups, the primary end-point is at the end of the 3-month analysis 
period, at which point graft function and proteinuria will be analysed.  At this point, the period of 
defined intervention will cease and patient treatment beyond this will be decided solely on clinical 
grounds, though observations will continue on individual patients for up to three years post-
recruitment.   
 
7.2 Number of Centres 
Multi-centre trial coordinated from King’s College London, Guy’s Hospital campus. 
7.3 Number of Subjects 
Study requires 30 patients to complete phase 2 and this will mean recruiting approximately 120 into 
the run-in period (phase 1).   
7.4 Sample size determination 
It is expected that up to 20% of the group randomised to remain on standard treatment may stabilise 
(because stabilisation on standard therapy may occur beyond the run-in period), whereas it is 
anticipated that approximately 70% of those receiving rituximab will stabilise.  Based on these 
estimations, at least 15 patients, randomised to each arm will need to reach the primary endpoint to 
detect these differences at 80% power and 5% significance.  In other words, 30 patients recruited to 
the randomisation phase of the study will need to reach the primary endpoint. Assuming that 25% 
of the patients recruited to the run-in phase will fail to stabilise by the end of the run-in period, it is 
estimated that approximately 120 patients will need to be enrolled. 
7.5 Randomisation (and blinding) 
Randomisation will be by permuted block method with concealment of block size. Randomisation 
will be stratified by graft function and proteinuria to ensure equal numbers with deteriorating 
function and isolated proteinuria are allocated to each arm. 
On local sites, the PI will evaluate patient progress after the run-in period, allocate appropriate 
patients to the ‘continued deterioration’ group, obtain patient consent to progress to phase 2, and 
then contact the Chief Investigator who will allocate the patient to the appropriate arm of phase 2 
(see 8.3). 
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7.6 Study duration 
Each subject will be recruited into the run-in phase (phase 1).  This will consist of an initial phase 
lasting 1-2 months, during which standard treatments will be optimised, followed by a period of 3 
months at optimal doses.  At the end of this period, participants will have either ‘passed’ run-in (i.e. 
stabilised graft function and/or reduced proteinuria), in which case they will be followed for a 
further 31-32 months (i.e. pass straight to phase 3) (total = 3 years post-recruitment), or ‘failed’ run-
in, in which case they will be eligible for phase 2. The primary endpoint is at the end of a formal 3-
month analysis period for each group, which begins on the day of randomisation for the control 
group and one month after the last dose of rituximab in the rituximab group, though all patients will 
be followed up for a total of 3 years post-recruitment. 
7.7 Study objectives 
7.7.1 Primary objective 
To determine whether anti-CD20 therapy can stabilise or improve renal function and/or reduce 
proteinuria in patients with C4d+/-, chronic (humoral) rejection in whom standard therapeutic 
approaches have failed. 
7.7.2 Secondary objectives 
To compare patient and graft survival between control and rituximab-treated groups 
To evaluate the adverse effect profile of rituximab in this group 
To correlate changes in circulating B cell numbers, anti-HLA and non-HLA Ab profiles and titre 
with responses to standard therapy and / or rituximab 
To correlate changes in T cell responsiveness to alloantigens with responses to standard therapy and 
/ or rituximab 
7.8 Study endpoints 
7.8.1 Primary endpoints 
Determined 3-5 months post-randomisation 
•Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, on samples 
taken in the preceding 3 months. 
•Change in degree of proteinuria, where present 
 
7.8.2 Secondary endpoints 
Secondary endpoints will be determined at 3-5 months post-randomisation and at 1, 2 and 3 years 
post-recruitment; 
• Rate of deterioration in renal function, defined by slope of reciprocal creatinine plot, using 
samples taken since the previous assessment 
• Patient survival  
• Graft survival 
• Incidence of culture positive infection 
• Incidence of malignancy 
• Change in degree of proteinuria, where present 
• Changes in circulating CD20+ cells in peripheral blood (measured monthly after rituximab until 
numbers recovered). 
• Changes in anti-graft Ab titres (measured every three months). 
• Changes in T cell responsiveness to alloantigens (measured every three months). 
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7.9 Trial treatments 
7.9.1 Optimal ‘standard therapy’ 
During the initial phase of the run-in period, the following standard clinical therapies will be 
introduced and/or optimised according to the following guidelines; 
 
• Mycophenolate mofetil bd, or enteric coated mycophenolic acid bd, with dose determined 
according to local unit guidelines.  In those centres monitoring MPA levels, dose will be titrated to 
achieve plasma 12-hour post-dose levels of 1.6-2.75.  In these centres, the starting dose will be 
500mg bd in patients not already on MMF 
• Tacrolimus bd titrated to achieve 12-hour post-dose levels of 4-8.  Starting dose 0.05mg/kg bd in 
patients not already on Tacrolimus 
• Statin therapy to achieve total non-fasting cholesterol to ≤ 4.5 
• ACE-I and ARB combination therapy to achieve a target bp of ≤140/≤80 
 
Therapy will be introduced on an intention to treat basis and tailored precisely to the individual 
patient, according to compliance, tolerance and achievement of target levels. 
 
7.9.2 Patients who fail to stabilise on optimal ‘standard therapy’ 
Patients with continuing deterioration or persisting or worsening proteinuria or both who get 
randomised to the control arm will remain on their individualised optimal therapy. 
Patients randomised to the rituximab arm will remain on their individualised optimal therapy and 
receive two intravenous infusions of rituximab (1g each) 14 days apart, so that the last dose is given 
as early as possible but definitely within 1-month post-randomisation. 
 
All drugs will be supplied in standard packaging and labelled by the appropriate hospital pharmacy 
in the same way as all other drugs. 
 
7.10 Criteria for Discontinuation 
7.10.1 Individual subject 
Subjects can withdraw at any time if they wish.   Failure to tolerate one or more components of the 
standard therapy in the run in period will not be seen as a reason to discontinue the trial but will be 
anticipated as an integral part of individualising therapy.  
Patients will not receive a second dose of rituximab if they suffer one of the following adverse 
effects following the first dose: pulmonary infiltrates, interstitial pneumonia, acute respiratory 
distress syndrome, myocardial infarction, cardiac arrhythmia, hypotension, angioedema, 
bronchospasm, hypoxia.  These patients will continue to be monitored as if they had received both 
doses in the rituximab arm. 
  
7.10.2 Trial 
The randomisation to receive rituximab will be halted temporarily if any one of the following 
occurs; 
• a patient death attributable to rituximab infusion. 
• unacceptable incidence of severe side effects attributable to rituximab infusion (see 7.10.1 – if 
occurring in >10% patients). 
In these instances, the trial will undergo urgent review by the External data monitoring committee. 
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The randomisation to stay on standard therapy alone will be discontinued if it becomes apparent, on 
intermittent analysis of the primary endpoint data, that there is a highly statistically significant 
difference in response rates in those patients receiving rituximab compared to standard therapy 
alone. 
8 SELECTION AND WITHDRAWAL OF SUBJECTS 
 
8.1 Inclusion Criteria 
 
To be included in the study the patient must have: 
•A functioning kidney allograft (with estimated (e) GFR by MDRD >20) and be >6/12 post-
transplantation 
•Deteriorating allograft function as defined by linear regression of reciprocal creatinine plot. 
Deterioration will be defined as a negative slope over at least the preceding 3 months (with at least 
6 creatinines included) with an adjusted r2 >0.35 and a p value of ≤0.05 compared to horizontal 
baseline. Deterioration will be confirmed by reduction in Cockroft-Gault (CG) eGFR over the same 
period (to exclude increases in body mass as a cause of a negative slope on reciprocal creatinine 
plots) OR significant proteinuria as assessed by a urine protein/creatinine ratio of ≥50. 
•CAN, by Banff ’97 criteria, or transplant glomerulopathy on renal allograft biopsy performed 
within 6/12 of enrolment  
•Diffuse, linear C4d deposition (on at least 25% of peritubular capillary (PTC) and/or glomerular 
EC of renal transplant biopsy when assessed by immunoperoxidase OR >50% of PTC (alone) when 
assessed by immunofluorescence) OR PTCitis OR glomerulitis with combined PTC/g score of ≥2. 
 
8.2 Exclusion Criteria 
 
The presence of any of the following will preclude patient inclusion 
 
•<18 years of age 
•suspicion of pregnancy confirmed by positive HCG pregnancy test 
•untreated ureteric obstruction on ultrasound of allograft 
•history of acute allograft rejection in preceding 3/12 
•history of MI in preceding 3/12 
•history of malignancy in previous 5 years (excluding tumours limited to skin) 
•symptomatic IHD 
•recipient of simultaneous pancreas/kidney transplant 
•recipient of ABO-incompatible kidney 
•recipient who underwent an HLA desensitisation procedure prior to transplantation 
•evidence, on examination of renal allograft biopsy specimen, of recurrent or de-novo disease 
(except IgA deposition in absence of mesangial proliferation)  
• evidence, on examination of renal allograft biopsy specimen, of CNI toxicity IF ACCOMPANIED 
by mostly supra-therapeutic CNI trough levels in the 6-month period preceding biopsy. 
• documented allergy to mouse or chimeric human/mouse proteins 
• HepBsAg+, HCV Ab+, HIV+ or HepBcAb+ 
• administration of lymphocyte depleting antibody within 3 months of enrolment 
 
8.3 Assignment and Randomisation. 
• Patient numbers will be allocated according to the order of recruitment at each site and will 
include a site-specific prefix.   
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• For randomisation, sequentially numbered opaque envelopes, sealed by an independent third 
party, will be held by the chief investigator.  The envelopes will be opened after patients have 
consented to phase 2. Patients will be allocated a randomisation number that will be cross-
referenced to the patient number. Randomisation will be stratified by graft function and proteinuria 
to ensure equal numbers with deteriorating function and isolated proteinuria are allocated to each 
arm. 
• Patients who voluntarily withdraw from phase 2 before the primary endpoint (see 8.5) will be 
replaced by another patient eligible for phase 2. 
8.4 Method of Blinding 
Patient and staff will be aware of the treatment.  
 
8.5 Subject withdrawal criteria 
8.5.1 Criteria for withdrawal 
• Patients are free to withdraw consent at any time during the study.   
• Patients will be withdrawn from the study if, during phase 1 or 2, they develop a medical problem 
that necessitates significant change (reduction or enhancement) in their immunosuppressive 
medication or prevents them receiving the IMP.  
• The cases of patients who die during phase 1 or 2 will be assessed by the external data monitoring 
committee as soon as possible to determine whether the trial should be halted.  If the cause of death 
of a patient during phase 2  is deemed unrelated to the trial, they may be replaced in the analysis by 
another eligible patient.  
• Patients in phase 3 who return to dialysis or undergo pre-emptive renal transplantation will be 
withdrawn from the trial. 
8.5.2 Follow up of withdrawn subjects 
• All patients will undergo routine clinical follow up with appropriate monitoring 
• Withdrawal during phase 1 will automatically make patients ineligible for phase 2 and 3, but those 
withdrawing from phase 2 will continue into phase 3, unless they specifically withdraw from this 
phase also. 
• A patient eligible for phase 2, who refuses to consent to enter this phase, will be followed up 
through phase 3 unless they specifically withdraw from this phase also. 
• Patients who voluntarily withdraw consent for phase 2, at any stage before the primary end-point, 
will be monitored in phase 3 unless they specifically withdraw from phase 3.  
• Patients who voluntarily withdraw from phase 2 before the primary endpoint will be replaced by 
another patient eligible for phase 2. 
9 TREATMENT REGIMENS 
All women of childbearing age will be advised at enrolment to use effective contraception during 
the course of the study to avoid pregnancy. 
9.1 Dosage schedules 
9.1.1 Run-in period. 
All patients will undergo a period of optimisation of standard approved therapy, consisting of 
treatment with the following drugs, unless specifically contraindicated or prevented by a specific 
adverse event; 
•initiation or maintenance of ACE-1 and / or ARB therapy, along with other anti-hypertensive drugs 
if required, at appropriate doses, aiming for a target bp of <140/<80. 
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•initiation or maintenance of statin therapy, aiming for a target random whole-blood cholesterol of 
≤ 4.5. 
• initiation or maintenance of bd MMF or enteric coated MPA, (titrating 12 hour trough MPA levels 
to within the range 1.6-2.75 in those centres monitoring MPA levels) 
•initiation or maintenance of bd tacrolimus, titrating 12-hour trough levels to within the range 4-8 
In addition, those patients who have had a step-up’ in their immunosuppression will be given anti-
infective prophylaxis according to local unit guidelines. 
There are no restrictions on the use of other medications. 
9.1.2 ‘Passed’ run-in period 
All patients maintained as above 
 
9.1.3 ‘Failed’ run-in period 
Control group – all patients maintained as above 
Rituximab group – maintenance of all run-in drugs.    
As prophylaxis against a first dose reaction, paracetamol 1g and chlorphenamine 
(chlorpheniramine) 10mg i.v. will be given to all patients 30 minutes before the first infusion of 
rituximab.  In addition, in those patients with a history of previous exposure to chimeric proteins 
(such as dacluzimab, basiliximab), hydrocortisone 100mg i.v. will also be given at the same time. 
Patients will be monitored with pulse, blood pressure, and oxygen saturation during the first dose 
infusion. 
All patients will receive 2 infusions of rituximab, separated by 14 days, at a fixed dose of 1g per 
dose, diluted in 250-500ml saline. The initial rate is 50mg/hour, escalating after 30 minutes to 
100mg/hour, and then increasing by 50 mg/hour to a maximum of 400mg/hour.  If side effects 
appear the rate of infusion should be halved or stopped (after discussion).   
NOTE: If bronchospasm, hypoxia, or severe dyspnoea occur the infusion should be stopped 
immediately and help sought from a senior doctor. 
All patients receiving rituximab will receive co-trimoxazole (or an appropriate alternative) 
prophylaxis for 6 months from the first dose at a dose according to unit protocol. 
  
 
9.1.4 Route of Administration 
All run-in drugs given orally 
Rituximab given by IV infusion 
9.1.5 Maximum dosage allowed 
Run-in drugs – dosages determined by unit protocols, clinical response and/or need to achieve 
target levels as stated 
For the rituximab - two 1g doses separated by 14 days 
 
9.1.6 Maximum duration of treatment of a subject 
Run-in drugs will be maintained at the individual-tailored optimal until the primary endpoint, 
though optimal treatments for each individual may change according to clinical or laboratory 
indication.  Beyond the primary endpoint, dosing regimens and targets will be the responsibility of 
the individual clinician primarily responsible for patient care.  
Maximum of two doses of rituximab over two weeks will be given to the experimental group 
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9.1.7 Procedures for monitoring subject compliance 
For run-in drugs, BP, cholesterol and drug trough level monitoring will be performed at each clinic 
visit. 
For rituximab, each dose will be given under direct supervision. 
 
9.2 Dosage modifications 
 
See 9.1 – standard therapy drug doses will be altered according to the criteria already outlined or 
according to local unit protocol where not determined by study protocol. 
In those patients who suffer a severe adverse reaction to first dose of rituximab, the second dose 
will be omitted.  These patients will continue to be followed up as stated. 
 
9.3 Legal status of the drug 
 
Rituximab is a licensed drug, but not for chronic allograft nephropathy and this study will be 
conducted under a clinical trials authorisation from the MHRA. All the ‘standard care’ drugs are 
being used within their licensed indications. 
 
9.4 Drug storage and supply 
 
All run-in drugs will be supplied as is our current clinical practice, by the hospital pharmacy 
initially and subsequently the patient’s local pharmacy.   
 
The Investigator is responsible for ensuring that all IMPs received at the site are inventoried and 
accounted for throughout the study. The IMP will be dispensed to the clinician and any returns of 
IMP must be documented on the drug accountability form. IMP will be supplied only to subjects 
participating in the study. Study drugs must be handled in strict accordance with the protocol and 
the product label and will be stored in a limited access area or in a locked cabinet under appropriate 
environmental conditions. Prior to administration, the dose and expiry date will be checked and the 
lot number noted. 
 
Unused study drug and study drugs returned (if applicable), must be available for verification by the 
sponsor’s site monitor during site monitoring. The destruction of unused study drug (both expired 
or unexpired) or used returned study drug will have to be authorised by the sponsor, and will be 
documented. The Sponsor may authorize to destroy on site according to local policy. 
 
9.5 Concomitant therapy 
 
Anti-infective drugs, to provide prophylaxis against infection in patients who have had a ‘step-up’ 
in their immunosuppression will be used according to the standard protocol of individual units, 
except in the case of those receiving rituximab, in which case all patients will receive 6 months 
prophylaxis with co-trimoxazole (or an appropriate alternative), with the dose determined by 
individual unit protocol. 
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10 STUDY PROCEDURE AND ASSESSMENTS 
10.1 Screening evaluation 
Patients who fulfil the basic entry criteria will be identified at the weekly biopsy meeting or on 
discussion with the histopathologist.  These individuals will have been referred for a biopsy on the 
basis of either proteinuria or deteriorating renal function, after appropriate exclusion of other 
causes, and will meet the histopatholgical criteria. 
 
10.2 Informed consent 
The notes of patients meeting the histopathological criteria will be reviewed by one of the 
investigators who will then arrange to see the patient, to address the other inclusion and exclusion 
criteria.  Patients will be given the information sheet and will have the opportunity to return for a 
second consultation within a few days to give informed consent for recruitment into the study.  
Patients undergoing randomisation will be consented a second time to ensure they understand the 
nature of the randomisation process and the difference between the two study arms. 
10.3 Baseline data 
All patients will have a full medical history taken and a clinical examination .The following are to 
be recorded: 
 
a) Weight and bp 
b) Sex and ethnicity 
c) Age and date of birth 
d) HLA type and that of donor kidney 
e) Any significant past medical history, including cause of renal failure, details of previous 
transplants and cause of graft loss, evidence of sensitisation pre-transplantation (PRA and 
antibody specificities if known) and previous exposure to chimeric or mouse proteins and of 
documented allergy to these (patients with a documented allergy are to be excluded from the 
study) 
f) Full blood count (including platelets and differential white cell count) 
g) Biochemical series (including urea, creatinine, uric acid, electrolytes, calcium, alkaline 
phosphatase, AST, CRP, lipid profile).  Serial serum creatinines will be imported into an 
excel spreadsheet to draw a reciprocal creatinine plot. 
h) MDRD eGFR on latest creatinine and CG eGFR estimated on the range of creatinines 
used to draw the reciprocal creatinine plot 
i) 12 lead ECG 
j) Protein: creatinine ratio on urine sample 
k) Separate blood samples will be taken for non-routine analysis of antibody status and for 
PBMC separation 
l) The renal biopsy will be analysed for non-routine light microscopy, immunofluorescence, 
immunoperoxidase and electron microscopy. 
m) Stored blood, serum or histopathology samples, if available, will be analysed as current 
samples to get retrospective data on histology and immune characteristics. 
 
10.4 Study assessments 
10.4.1 Timing of assessments 
Up to the primary end-point, patients will be seen ideally every two weeks for routine clinical 
assessments, appropriate for all patients who have had a change in medication including in 
immunosuppressive therapy. Patients entering the randomisation phase will have monthly analyses 
Protocol Number: 06/Q0406/119  Page 44 of 55 
Protocol Short title ‘RituxiCAN-C4’  Version Number:10  Version Date 01-05-2013 
of circulating B cell numbers until either the primary endpoint (for patients randomised to 
continued optimal care) or until B cell numbers have recovered to pre-treatment levels (for those 
randomised to receive rituximab). Formal study assessments will be performed at the end of the 
run-in period and at the primary end point and ideally will occur at one of these standard transplant 
clinic follow-up appointments, rather than at extra visits. Beyond the primary endpoint, routine 
follow up will be at intervals determined by the clinical condition of the patient.  Study assessments 
will occur every 3 months for 3 years post-recruitment. 
10.4.2 Assessment data,   
 
The following are to be recorded during formal study assessments: 
 
a) Weight and bp 
b) Age  
c) Evidence of drug toxicity, confirmed infection or malignancy during previous 3 months 
(or since last assessment) and action taken. 
d) Abnormalities of the full blood count during previous 3 months (or since last formal 
assessment) and action taken.  
e) Abnormalities of biochemical series (including urea, creatinine, uric acid, electrolytes, 
calcium, alkaline phosphatase, AST, CRP, lipid profile) during previous 3 months (or since 
last formal assessment) and action taken.  Serial serum creatinines will be imported into an 
excel spreadsheet to draw a reciprocal creatinine plot. 
f) MDRD eGFR on latest creatinine and CG eGFR estimated on the range of creatinines 
used to draw the updated reciprocal creatinine plot 
g) 12 lead ECG 
h) Protein: creatinine ratio on urine sample 
i) In those patients who have returned to long-term dialysis or re-transplanted, date of first 
dialysis (or of –re-transplantation) and time from enrolment will be recorded. 
j) Separate blood samples will be taken for non-routine analysis of antibody status and for 
PBMC separation 
 
 
10.4.3  Renal Biopsy 
There is no formal requirement for a renal biopsy at any time during the study, although enrolment 
does not prevent transplant renal biopsies being performed on clinical grounds, (for example to rule 
out the development of BK nephropathy in patients who have had immunosuppression increased). 
10.5 Post study examination 
No formal post-study examination required as data will be available from ongoing routine clinical 
visits 
 
 
11 EVALUATION OF RESULTS  
11.1 Response criteria 
 
11.1.1 Rate of deterioration of renal function 
This will be determined by linear regression analysis of the 1/creatinine plot according to the 
criteria used by Dudley in the creeping creatinine study (1).  This requires analysis of at least 6 data 
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points over three months, with deterioration defined as a negative slope.  To be valid, the linear 
regression should yield an adjusted r2 value of ≥0.35 and have a p value of ≤0.05 compared to a 
horizontal baseline.  The data obtained at the end of run-in period and subsequently at the primary 
and secondary endpoints will be compared to that obtained at baseline.  A reduced rate of 
deterioration will be defined as a change in the slope of the curve so that it becomes less negative 
(i.e. it moves towards the horizontal baseline but is still significantly different from the baseline 
(p≤0.05).  At the end of the run-in period, patients with these data will undergo randomisation. 
Stabilisation in renal function will be defined as a change in the slope so that it is not significantly 
different from the horizontal baseline (i.e. p > 0.05 on linear regression analysis).  An improvement 
in renal function will be defined as a change in the slope so that it becomes positive.  To rule out 
changes in body mass (which influences plasma creatinine levels) as a cause of the change in slope 
of the reciprocal creatinine plot, CG eGFR will be performed on the study creatinines at each study 
assessment. 
11.1.2 Survival (patient and graft) 
These will be measured from the date of recruitment and will be reported for all deaths and graft 
failures due to all causes.  Graft failure will be defined as the return to long-term dialysis or re-
transplantation.  The cause of death or graft failure is thus to be recorded in all instances. 
 
11.1.3 Infection 
This will be defined as a positive microbiological culture or other test confirming viral, bacterial or 
fungal replication in association with specific symptoms.  Also, clinical episodes with confirmatory 
imaging of infection (for instance, consolidation on lung imaging) will be regarded as an infective 
episode and recorded. 
11.1.4 Malignancy 
This will be defined by histopathological confirmation of malignancy on a biopsy of any suspicious 
lesion.  
11.1.5 Proteinuria 
This will be defined by the protein:creatinine ratio of a urine sample and is significant if >50. The 
data obtained at the end of run-in period and subsequently at the primary and secondary endpoints 
will be compared to that obtained at baseline.  Reduction in proteinuria will be defined by a 
protein:creatinine ratio that has fallen to <50. Worsening proteinuria will be defined as a 
protein:creatinine ratio that has increased.  Persistent proteinuria will be defined by a 
protein:creatinine ratio that has remained >50, even if it has changed from the previous 
measurement.  At the end of the run-in period, patients with persisting or worsening proteinuria will 
undergo randomisation. 
11.1.6 Circulating B cells 
The number of circulating B cells per unit volume of blood will be determined by flow cytometry 
using CD20 and/or CD19 as a marker of B cells. 
11.1.7 Anti-graft antibodies 
Serum will be prepared from 20mls of clotted blood and stored in a dedicated freezer in marked 
aliquots.  The following analyses will be performed; Flow PRA screening and specific antigen tests, 
Luminex screen, lymphocytotoxic cross match using donor or surrogate donor material, anti-GBM 
antibodies, anti-MIC antibodies, anti-vimentin antibodies.  All these have been associated with 
CAN and chronic humoral rejection. 
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11.1.8 Changes in T cell responsiveness 
PBMC will be prepared from 50mls of heparinised or EDTA anticoagulated blood using standard 
laboratory protocols and used in proliferation and cytokine assays with donor or surrogate donor 
stimulator cells to address the role of B cells and CD25+ regulatory T cells in the allogeneic 
response.   
[NB For subjects that received a living kidney, where the donor is available, separate consent 
should be sought from the donor to provide blood specifically for this study] 
 
12 ASSESSMENT OF SAFETY 
12.1 Definitions 
12.1.1 Adverse event 
Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal 
product and which does not necessarily have a causal relationship with this treatment. 
An adverse event can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of an investigational 
medicinal product, whether or not considered related to the investigational medicinal product. 
 
12.1.2 Adverse reaction of an investigational medicinal product (AR) 
All untoward and unintended responses to an investigational medicinal product related to any dose 
administered. All adverse events judged by either the reporting investigator or the sponsor as having 
a reasonable causal relationship to the investigational medicinal product qualify as adverse 
reactions. The expression reasonable causal relationship means to convey in general that there is 
evidence or argument to suggest a causal relationship 
 
12.1.3 Unexpected adverse reaction 
An adverse reaction, the nature, or severity of which is not consistent with the applicable product 
information (e.g. investigator's brochure for an unapproved investigational product or summary of 
product characteristics (SmPC) for an authorised product). 
When the outcome of the adverse reaction is not consistent with the applicable product information 
this adverse reaction should be considered as unexpected. 
 
The term “severe” is often used to describe the intensity (severity) of a specific event. This is not 
the same as “serious,” which is based on patient/event outcome or action criteria. 
 
12.1.4 Serious adverse event or serious adverse reaction 
Any untoward medical occurrence or effect that: 
- results in death, 
- is life-threatening 
- requires hospitalisation or prolongation of existing inpatients´ hospitalisation, 
- results in persistent or significant disability or incapacity, 
- is a congenital anomaly or birth defect. 
 
Life-threatening in the definition of a serious adverse event or serious adverse reaction refers to an 
event in which the subject was at risk of death at the time of event; it does not refer to an event 
which hypothetically might have caused death if it were more severe. 
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12.2 Expected adverse drug reactions: Rituximab 
12.2.1 Cytokine release syndrome 
This is characterised by severe dyspnoea, sometimes accompanied by bronchospasm and hypoxia, 
in addition to fever, chills, rigors, urticaria, and angioedema.  In oncological practice, this has been 
associated with features of the tumour lysis syndrome, such as hyperuricaemia, hyperkalaemia, 
hypocalcaemia, acute renal failure, elevated LDH and may be associated with acute respiratory 
failure. 
12.2.2 Anaphylaxis 
Anaphylaxis can occur, typically within minutes of starting the infusion (which differentiates it 
from the cytokine release syndrome).  It is most likely in patients with human anti-mouse or human 
anti-chimeric antibody titres (caused by previous exposure to therapeutic antibodies, and hence 
rituximab will be used in caution, along with appropriate prophylactic therapy (see previously) in 
individuals exposed to other therapeutic antibodies). 
12.2.3 Hypotension 
Common during infusion of rituximab in tumour lysis setting. 
12.2.4 Cardiac toxicity 
Angina and cardiac arrhythmias such as atrial flutter and fibrillation, heart failure or myocardial 
infarction have been reported. 
 
12.3 Expected Serious Adverse Events-Rituximab 
The following are quoted in the SmPC as adverse events reported by at least 1% of 356 patients in 
clinical trials in the treatment of haematological malignancy.  In descending order of frequency:   
12.3.1 General 
Fever, chills, asthenia, headache, throat irritation, abdominal pain, back pain, flushing, chest pain, 
malaise, tumour pain, cold syndrome, neck pain. 
12.3.2 Cardiovascular system 
Hypotension, hypertension, tachycardia, arrhythmia, postural hypotension. 
12.3.3 Digestive system 
Nausea, vomiting, diarrhoea, dyspepsia, anorexia, dysphagia, stomatitis, constipation. 
12.3.4 Blood and lymphatic system 
Leukopenia, neutropenia, thrombocytopenia, anaemia. 
12.3.5 Metabolic and nutritional disorders 
Angioedema, hyperglycaemia, peripheral oedema, LDH increase, hypocalcaemia, face oedema, 
weight loss. 
12.3.6 Musculo-skeletal system 
Myalgia, arthralgia, hypertonia, pain. 
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12.3.7 Nervous system 
Dizziness, paraesthesia, anxiety, insomnia, vasodilatation, hypoaesthesia, agitation. 
12.3.8 Respiratory system 
Bronchospasm, rhinitis, increased cough, dyspnoea, chest pain, respiratory disease. 
12.3.9 Skin and appendages 
Pruritus, rash, urticaria, night sweats, sweating. 
12.3.10 Others 
Lacrimation disorder, conjunctivitis, ear pain, tinnitus 
12.3.11 Adverse events less common than 1% 
Coagulation disorders, asthma, bronchiolitis obliterans, hypoxia, abdominal enlargement, pain at the 
infusion site, bradycardia, lymphadenopathy, nervousness, depression, dysgeusia. 
 
12.4 Recording and evaluation of adverse events 
Individual adverse events should be evaluated by the investigator and, where indicated, they should 
be reported according to the processes outlined in sections 12.5 and 12.6. This includes the 
evaluation of its seriousness and the causality between the investigational medicinal product(s) 
and/or concomitant therapy and the adverse event. 
The sponsor, through the chief investigator, has to keep detailed records of all AEs reported to him 
by the investigator(s´) and to perform an evaluation with respect to seriousness, causality and 
expectedness. 
12.4.1 Assessment of seriousness 
Mild: The subject is aware of the event or symptom, but the event or symptom is easily 
tolerated 
Moderate: The subject experiences sufficient discomfort to interfere with or reduce his or her usual 
level of activity 
Severe: Significant impairment of functioning; the subject is unable to carry out usual activities 
and / or the subject’s life is at risk from the event. 
12.4.2 Assessment of causality 
Probable: A causal relationship is clinically / biologically highly plausible and there is a plausible 
time sequence between onset of the AE and administration of the investigational 
medicinal product and there is a reasonable response on withdrawal. 
Possible: A causal relationship is clinically / biologically plausible and there is a plausible time 
sequence between onset of the AE and administration of the investigational medicinal 
product. 
Unlikely: A causal relation is improbable and another documented cause of the AE is most 
plausible. 
Unrelated: A causal relationship can be definitely excluded and another documented cause of the 
AE is most plausible. 
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12.5 Reporting adverse events 
12.5.1 Who should report and whom to report to? 
King’s College London have delegated the delivery of the Sponsor’s responsibility for 
Pharmacovigilance (as defined in Regulation 5 of the Medicines for Human Use (Clinical Trials) 
Regulations 2004 to the Joint Clinical Trials Office (JCTO).  
All SAEs, SARs and SUSARs (excepting those specified in this protocol as not requiring reporting) 
will be reported immediately by the Chief Investigator to the (JCTO) in accordance with the current 
Pharmacovigilance Policy. The Chief Investigator will provide an annual report of all SARs (expected 
and unexpected), and SAEs which will be distributed to the sponsor via the JCTO, MHRA and the 
REC 
12.5.2 When to report? 
12.5.2.1 Fatal or life-threatening SUSARs 
The JCTO will report SUSARs (Suspected Unexpected Serious Adverse Reactions) and other SARs 
to the regulatory authorities (MHRA, competent authorities of other EEA (European Economic Area) 
states in which the trial is taking place. 
The Chief Investigator will report to the relevant ethics committees. Reporting timelines are as 
follows: 
- SUSARs which are fatal or life-threatening must be reported not later than 7 days after the sponsor 
is first aware of the reaction. Any additional relevant information must be reported within a further 
8 days. 
12.5.2.2 Non fatal and non life-threatening SUSARs 
- SUSARs that are not fatal or life threatening must be reported within 15 days of the sponsor first 
becoming aware of the reaction.   
The Chief Investigator will provide an annual report of all SARs (expected and unexpected), and 
SAEs which will be distributed to the Sponsor (JCTO), MHRA and the REC.. 
12.5.3 How to report? 
12.5.3.1 Minimum criteria for initial expedited reporting of SUSARs 
Information on the final description and evaluation of an adverse reaction report may not be 
available within the required time frames for reporting. For regulatory purposes, initial expedited 
reports should be submitted within the time limits as soon as the minimum following criteria are 
met: 
a) a suspected investigational medicinal product, 
b) an identifiable subject (e.g. study subject code number), 
c) an adverse event assessed as serious and unexpected, and for which there is a reasonable 
suspected causal relationship, 
d) an identifiable reporting source, 
and, when available and applicable: 
e) The EudraCT number: 
f) An unique case identification (i.e. sponsor's case identification number). 
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12.6 Responsibilities of Principal Investigators (PIs) and Chief Investigator (CI) in 
multicentre trial (see figure 1) 
• The PI on each secondary site will take responsibility for reporting all adverse events and 
pregnancy to the CI at the primary site. 
• All reports should be on the SAE form provided for the study. 
• As outlined above, the PIs are to distinguish between’ Adverse event’ (AE) and ‘serious adverse 
event’ (SAE).  The definition of ‘serious’ is contained in section 12.1.4 of the protocol. See the 
same section for definition of ‘life-threatening’ SAE’s. 
• Report all SAEs to CI, including those related to the IMP (rituximab) and those not related to 
IMP. 
• In deciding whether the AE is related to the IMP, the PI must report an AE as related to the IMP 
if there is a suspected causal relationship to the IMP (if the event is probably or possibly related). 
See section 12.4.2 above 
• Considering SAEs related to the IMP, PIs must distinguish between ‘expected’ SAE and 
‘unexpected’ SAE.  The definitions of ‘expected’ AEs are contained in sections 12.2 and 12.3 of the 
protocol. All other serious AEs are therefore ‘unexpected’.  
12.6.1 Reporting times 
• PI on secondary site must report all Suspected Serious AEs (expected or unexpected) related to 
IMP to CI on primary site as soon as they become aware 
• PI on secondary site must report all Serious AEs unrelated to IMP to CI on primary site as soon as 
they become aware of the event. 
• PI on secondary site must report all other AEs, related or unrelated to IMP, to CI on primary site 
within 28 days of being aware.  
• CI at the primary site will take responsibility for informing the JCTO on behalf of the sponsor, 
Main Research Ethics Committee and other interested parties within the required time frames of 
any event that require expedited reporting. 
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12.6.2 Figure 1 
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13 STATISTICS 
13.1 Study statistician 
Irene Rebollo Mesa, MRC Centre for Transplantation, King’s College London. 
13.2 Statistical methods to be employed 
Response rates in the control and study groups will be compared by Chi squared test 
Student’s t test for independent samples will be used to compare adverse events and other 
demographic data 
Log rank test will be used to compare patient and graft survival rates 
13.3 Interim analyses 
An interim analysis will be performed after 30 and 60 patients have been enrolled.  The King’s 
College London transplantation research committee will review progress and safety data at each 
meeting (approximately every two months).   
 
13.4 Number of Subjects to be enrolled 
Assuming that 20% of those randomised to the control arm settle spontaneously within the study 
period, and that 70% of those receiving rituximab stabilise, a two group chi-squared test with a 0.05 
one-sided significance level will have 80% power to detect this difference when 15 patients are 
randomised to each arm. So 30 patients will need to be enrolled into the randomisation phase. 
Based on the evidence available from small published studies and from the experience at the 
Hammersmith, it is anticipated that 25% of patients who undergo optimisation of standard 
immunotherapy will continue to deteriorate and thus be eligible for randomisation. Therefore, it is 
anticipated that approximately 120 patients will need to enter the run-in period of the study. 
13.5 Criteria for the termination of recruitment 
•When 30 patients randomised in phase 2 have reached the primary endpoint. 
 
Earlier termination will be considered by the External data monitoring committee on the following 
grounds: 
A significant excess of adverse events in the study arm. 
 A highly significant difference in response rates at interim analysis if one group is 
 faring significantly worse than the other 
13.6 Definition of the end of the trial 
The trial will be defined as finished when the last patient recruited reaches the end of the three-year 
follow-up period.  Within 90 days of completion, the local research ethics committee and the MHRA 
will be informed.  
 
 
14 DIRECT ACCESS TO SOURCE DATA / DOCUMENTS 
The Investigator(s) will permit trial-related monitoring, audits, REC review, and regulatory 
inspections (where appropriate) by providing direct access to source data and other documents 
 
15 ETHICAL CONSIDERATIONS 
 
Protocol Number: 06/Q0406/119  Page 53 of 55 
Protocol Short title ‘RituxiCAN-C4’  Version Number:10  Version Date 01-05-2013 
15.1 Consent 
All patients will freely give their informed consent to participate in the study. A patient may decide 
to withdraw from the study at any time without prejudice to their future care. 
 
15.2 Ethical committee review 
The study protocol is to be seen and approved by the appropriate ethical review committee(s) of any 
participating hospital. Copies of the letters of approval are to be filed in the study file. 
 
15.3 External Data Monitoring Committee 
• Consists of Chairman and two members from centres not involved in the trial. 
• All will be consultant physicians or surgeons with active clinical practise in renal transplantation. 
• Committee will review data and outcomes after randomisation of 10, 20 and 30 patients. 
• Committee will review all patient deaths during the course of the trial.  
15.4  Quality Assurance 
Monitoring of this trial to ensure compliance with Good Clinical Practice and scientific integrity will 
be managed and oversight retained by the Joint Clinical Trials Office Quality Team.  
 
15.5 Declaration of Helsinki Good Clinical Practise 
The study is to be carried out in conformation in accordance with the declaration of Helsinki 
(1996), and Good Clinical Practice as defined in the UK Clinical Trial Regulations.  
 
 
16 DATA HANDLING AND RECORD KEEPING 
All data will be held on a password-protected dedicated PC or laptop with additional back-ups on a 
password-protected secure server and appropriate magnetic or encrypted optical storage media.  
During the trial paper copies will be held in a locked filing cabinet in the chief investigators office 
and retained for 10 years following the end of the study.   
All trial data will be stored and archived in line with the Medicines for Human Use (Clinical Trials) 
Amended Regulations 2006 as defined in the Joint Clinical Trials Office Archiving SOP Record 
keeping will be the responsibility of the investigators.  
 
17 FINANCIAL AND INSURANCE  
The study will be indemnified by King’s College London for negligent and non-negligent harm.  In 
addition, Professor Dorling also has independent insurance with medical defence societies. 
 
A fellowship from the Medical Research Council UK provides salary for the trial Research Fellow 
and also provides funds to perform some of the non-routine analyses that are an integral part of this 
project.   Additional funds for other non-routine analyses have also been provided by the Roche 
Organ Transplantation Research Foundation, specifically to look for non-HLA-specific antibodies 
and to perform the PBMC and T cell analyses.  Roche have agreed to supply the IMP (rituximab) 
free of charge. 
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18 PUBLICATIONS POLICY 
 
The chief investigator will review all presentations and publications arising from this study and 
decide authorship in accordance with accepted guidelines.  Roche, as providers of the study drug, 
will be notified of any such material and have a right to view prior to presentation or submission. 
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Supplementary Figure 4 – Changes in DSA in patients included in primary EP 
analysis of the RCT (see supplementary figure 4 for the three patients in the 
Rituximab-treated group who were not included in in the primary endpoint 
analysis
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